Skip to main content
eLife logoLink to eLife
. 2020 Jan 14;9:e49817. doi: 10.7554/eLife.49817

TRF1 averts chromatin remodelling, recombination and replication dependent-break induced replication at mouse telomeres

Rosa Maria Porreca 1,2, Emilia Herrera-Moyano 1,2, Eleni Skourti 1,2, Pui Pik Law 1,2, Roser Gonzalez Franco 1,2, Alex Montoya 3, Peter Faull 3,4, Holger Kramer 3, Jean-Baptiste Vannier 1,2,
Editors: Raymund Wellinger5, Jessica K Tyler6
PMCID: PMC6986873  PMID: 31934863

Abstract

Telomeres are a significant challenge to DNA replication and are prone to replication stress and telomere fragility. The shelterin component TRF1 facilitates telomere replication but the molecular mechanism remains uncertain. By interrogating the proteomic composition of telomeres, we show that mouse telomeres lacking TRF1 undergo protein composition reorganisation associated with the recruitment of DNA damage response and chromatin remodellers. Surprisingly, mTRF1 suppresses the accumulation of promyelocytic leukemia (PML) protein, BRCA1 and the SMC5/6 complex at telomeres, which is associated with increased Homologous Recombination (HR) and TERRA transcription. We uncovered a previously unappreciated role for mTRF1 in the suppression of telomere recombination, dependent on SMC5 and also POLD3 dependent Break Induced Replication at telomeres. We propose that TRF1 facilitates S-phase telomeric DNA synthesis to prevent illegitimate mitotic DNA recombination and chromatin rearrangement.

Research organism: Human, Mouse

Introduction

Telomeres are specialised nucleoprotein structures at the ends of chromosomes, composed of repetitive sequences (TTAGGG repeats in mammals) (Moyzis et al., 1988), long non-coding RNA called TERRA and six associated proteins, TRF1, TRF2, POT1a/b, RAP1 and TIN2, that form the shelterin complex (de Lange, 2005). These capping structures have the crucial function of maintaining genome stability by protecting the chromosome end from being recognised as DNA double strand breaks (DSBs) (Palm and de Lange, 2008). They also represent challenging structures for the replication machinery, which is associated to telomere fragile sites (Martínez et al., 2009; McNees et al., 2010; Sfeir et al., 2009; Vannier et al., 2012). Telomere fragility is identified by the formation of multitelomeric signals (MTS), where telomeres appear as broken or decondensed, resembling the common fragile sites (CFS) observed at non telomeric loci after treatment with aphidicolin (APH). TRF1 facilitates the progression of the replication fork at telomeres, by recruiting a specialised DNA helicase BLM, which in turn resolve secondary structures, similar to fission yeast ortholog Taz1 (Lee et al., 2018; Martínez et al., 2009; Miller et al., 2006; Sfeir et al., 2009).

During tumorigenesis, cancer cells can achieve replicative immortality by activation of telomere maintenance mechanisms. The majority of cancer cells reactivate telomerase, while a minority (10–15%) uses an alternative mechanism named ALT for alternative lengthening of telomeres (Bryan et al., 1997; Kim et al., 1994). Intriguingly, ALT is characterised by the appearance of ALT-associated PML bodies (APBs), specialised sites where a subset of telomeres co-localises with PML protein and several DNA repair and homologous recombination (HR) proteins (Draskovic et al., 2009; Wu et al., 2000; Yeager et al., 1999). ALT telomeres can be maintained by more than one mechanism of recombination. Indeed, in yeast, two different ALT-like pathways have been described: type I and type II, both dependent on Rad52. While Type I requires Rad51 to mediate the invasion of a homologous sequence, Type II is Rad51 independent but Rad50 (of the MRX/N complex) dependent. Both Type I and II mechanisms require the DNA polymerase Pol32, which initiates DNA synthesis for several kilobases, in a process known as Break Induced Replication (BIR) (Ira and Haber, 2002). Recently, multiple groups have revisited this Rad51 independent DNA synthesis repair pathway at mammalian ALT telomeres (Dilley et al., 2016; Garcia-Exposito et al., 2016; Roumelioti et al., 2016). Mammalian BIR is dependent on POLD3 and POLD4, subunits of DNA polymerase delta and orthologs of yeast Pol32. ALT cells present increased DNA damage response (DDR) and several studies have underlined the contribution of replication stress to ALT-mediated telomere extension (Arora et al., 2014; Cox et al., 2016; Pan et al., 2017). However, the molecular mechanisms initiating recombination in ALT cells are still unclear.

In order to gain insight into the chromatin composition of telomeres undergoing replication stress, we performed Proteomics of Isolated Chromatin segments (PICh), using TRF1 conditional knock-out Mouse Embryonic Fibroblasts (MEFs, telomerase positive). Surprisingly, we found that telomeres lacking TRF1 are enriched in SMC5/6, DNA polymerase δ (POLD3), and chromatin remodelling factors known to be associated with ALT telomeres. These cells also present additional DNA damage and recombination hallmarks such as formation of APBs, mitotic DNA synthesis at telomeres, a feature of BIR and increased TERRA levels. Further investigation using specific shRNAs against the SMC5/6 complex or POLD3 revealed how these two complexes are key regulators of the recombination signature identified in TRF1 deleted cells. Taken together, these results strongly identify TRF1 as a central player in preserving telomeric chromatin against HR, induced by DNA replication stress, and particularly POLD3 dependent-mitotic DNA synthesis.

Results

Capture of TRF1 depleted telomeres by PICh reveals drastic changes in the chromatin composition

To isolate and identify the chromatin composition of TRF1 depleted telomeres, we employed Proteomics of Isolated Chromatin segments (PICh), a powerful and unbiased technique that uses a desthiobiotinylated oligonucleotide complementary to telomeric repeat sequences to specifically pull down telomeric chromatin (Déjardin and Kingston, 2009). We performed PICh in MEFs harboring a TRF1 conditional allele. MEFs lacking TRF1 are well known to undergo replicative stress; however, they can grow for up to 8 days before entering senescence, making them optimal for investigating replication stress at telomeres (Martínez et al., 2009; Sfeir et al., 2009). Cells were transduced twice (day 0 and 3) with a CRE or GFP control adenovirus and collected 7 days after the first transduction, as indicated in the timeline (Figure 1A). Excision of exon 1 of TRF1 by CRE recombinase (Sfeir et al., 2009) resulted in the expected loss of TRF1 protein as determined by immunoblotting and deficient cells do not show drastic change in the cell cycle distribution (Figure 1—figure supplement 1). Cells were fixed and isolation of telomeres was performed using a probe complementary to TTAGGG repeats or a scrambled probe as a negative control. Finally, telomeric chromatin was isolated from both control cells (wt) and TRF1 deleted cells before mass spectrometry identification (Figure 1C). We identified a list of 1306 proteins that was subjected to refinement in order to remove unspecific bound proteins or contaminants found with the scrambled probe (see experimental procedure for detailed description). Based on the analysis of label free quantification (LFQ intensities), we found 119 proteins presenting a gain of abundance at TRF1 depleted telomeres (Log2<-2) and 206 factors were displaced from these telomeres (Log2>-2), considering that a cut-off for differential expression is set to log2 fold change (TRF1deletion/wt)> |2| and -Log (p-value) > 1 (Figure 1D). Amongst these 206 proteins, we found TRF1, as expected due to the knock-out of its gene, but also one component of the CST complex (CTC1), important player in the efficient restart of stalled replication forks at telomeres (Gu et al., 2012) and recruited through POT1b interaction (Wu et al., 2012). Interestingly, POT1b is also less abundant at TRF1 depleted telomeres (Figure 1D–E). On the other end, the group of 119 proteins enriched in TRF1 deleted cells includes several factors involved in structural maintenance of chromosomes (SMC), HR and DNA damage response (Figure 1D–E–F), such as the MRN complex (MRE11, RAD50 and NBS1). The identification of 53BP1 recruited to TRF1 depleted telomeres (Figure 1D–F) acts as a positive marker for the specificity of this proteomic analysis, as reported before in Martínez et al. (2009); Sfeir et al. (2009). Moreover, we could identify drastic and previously uncharacterised changes of the telomeric proteome at telomeres undergoing replication stress presented hereafter.

Figure 1. Proteomics of isolated chromatin segments (PICh) of TRF1 depleted mouse telomeres.

(A) Overview of experimental timeline aimed at performing PICh experiment after induction of TRF1 deletion. TRF1F/F MEFs were infected twice (day 0 and 3) with adenovirus containing either GFP-control or CRE and collected at day 7 for PICH experiments. (B) Western blot showing deletion of TRF1 in MEFs after infections with CRE Adenovirus, at day 7 as in A. (C) Schematic representation of the PICh analysis performed to detect chromatin changes occurring at telomeres upon TRF1 deletion. (D) Volcano Plot based on LFQ intensities of proteins. Cut off for differential expression were set to log2 fold change (TRF1deletion/wt)> |2| and -Log (p-value) > 1. (E) Table listing shelterin components and some of the DNA damage response (DDR) factors identified. The corresponding number of unique peptide isolated is indicated for each factor of interest. Relative LFQ intensity abundance profiles were visualised in the form of a heat-map, by scaling each protein intensity to the maximum intensity across conditions. Light to darker colours indicate increasing relative protein abundance. (F) Connectivity map for proteins recruited at telomeres upon TRF1 deletion using string-db.org software. Solid lines, represents strong direct interactions, while dashed lines represent no evidence for direct interaction. In violet, DNA damage and repair proteins; in orange, factors belonging to DNA repair specifically involved in DNA recombination process; while in green and red, important factors for chromosome maintenance and factors involved in RNA metabolism, respectively. Source data are provided as a Source Data File.

Figure 1—source data 1. TRF1F/F MEFs western blot.
Related to Figure 1B.
Figure 1—source data 2. PICh data (TRF1F/F telo vs TRF1-/- telo).
Related to Figure 1D.
elife-49817-fig1-data2.xlsx (227.8KB, xlsx)
Figure 1—source data 3. PICh data.
Related to Figure 1F.
elife-49817-fig1-data3.xlsx (219.7KB, xlsx)

Figure 1.

Figure 1—figure supplement 1. TRF1 deficient MEFs show no drastic changes in their cell cycle.

Figure 1—figure supplement 1.

The cell cycle status of TRF1F/F MEFs infected with GFP or CRE adenovirus was examined via flow cytometry. DNA was stained with propidium iodide and cells were incubated with EdU to mark newly synthesized DNA. Gates delineate the different stages of the cell cycle. The present graph displays data from 10,000 cells of 2 independent biological replicates.

TRF1 suppresses APBs formation and HR at telomeres

Interestingly, TRF1 deficient MEFs present a telomeric enrichment for factors involved in HR and chromatin remodelling (BRCA1, PML, SMC5/6, ATRX and, NurD associated factors) that are usually abundant at ALT telomeres (Figure 2A) (Conomos et al., 2014; Draskovic et al., 2009; Marzec et al., 2015; Potts and Yu, 2007). To validate the specific association of some of these factors with TRF1 depleted telomeres in telomerase positive MEFs, we carried out chromatin immunoprecipitation (ChIP) experiments using ChIP-grade specific antibodies followed by telomeric dot-blot. TRF1 antibody was used as a negative control for our experiment, while the recruitment of BAZ1b, BRCA1 and some subunits of the nucleosome remodelling and deacetylase (NurD) complex (p66a, MTA1, ZNF827 and CHD4) was assessed. For all these factors, with the exception of p66a for which no statistical significance was achieved, we observed a specific enrichment at telomeres upon TRF1 deletion (Figure 2—figure supplement 1, A). In addition, to confirm the presence of PML at telomeres lacking TRF1, as suggested by our PICh data (Figure 2A), we performed immuno-FISH and scored for the formation of APBs. We observed a two-fold increase in the number of co-localisations between PML and telomeres in TRF1-/- MEFs compared to control cells (Figure 2C). To test if the recruitment of some of these factors is a consequence of chronic replication stress or if TRF1 directly inhibit these events, we treated wt MEFs with low doses of APH (0.4 µM) for 3 days. Using ChIP-dot blot, we did not detect the recruitment of any of the chromatin remodellers and DNA repair factors BRCA1, MTA1, CHD4, ZNF827 and BAZ1b, present at TRF1 depleted telomeres (Figure 2—figure supplement 1, B). Furthermore, we show that wt MEFs treated with APH do not form APBs despite a general increase in PML foci (Figure 2—figure supplement 1, C). Overall these data demonstrate that telomeres depleted of TRF1 engage chromatin remodelling associated with the formation of APBs, platform of recombination (Cesare and Reddel, 2010). Hence, to test if TRF1 is a suppressor of recombination, we revisited the incidence of telomeric sister chromatid exchanges (T-SCE) using chromosome orientation FISH (CO-FISH) in TRF1 deficient cells (Figure 2D). We identified an increase in T-SCE in TRF1-/- MEFs (2.8%) compared to control cells (0.4%) (Figure 2D). This result is at odds with previous publications where T-SCE events detected at TRF1 depleted telomeres were not significantly enriched, with only 1% of T-SCEs detected compared to 0.1% in wt cells (Martínez et al., 2009; Sfeir et al., 2009). In fact, this discrepancy might be explained by the difference in timing for the analysis of T-SCEs in TRF1 deficient cells. Both publications report the lack of recombination effect by T-SCEs at 3 or 4 days after TRF1 loss, while we generally carry our investigations at day 7. Therefore, we repeated the experiments in TRF1-/- cells at different time points post infection: day 4 and day 7, finding respectively 1.6% and 2.8% of T-SCEs per chromosome end (Figure 2—figure supplement 2, A-left graph), indicating a lower % of T-SCE events happening at earlier time point. A second distinct difference with previous reports is the type of telomere signal exchanges that we analysed. As in Sfeir et al. (2009), all types of telomere signal exchanges (e.g. the exchanges appearing at single chromatids and the reciprocal exchanges at both chromatids) were considered. However, Martínez et al. (2009) only refers to reciprocal exchanges at both chromatids. Thus, we next classified T-SCEs detected in TRF1 deficient MEFs into these two different types (single and double) and found that 4 days post infection only T-SCEs at single chromatids were significantly increased (Figure 2—figure supplement 2, A-right graph), while the reciprocal exchanges were not enhanced at TRF1 depleted telomeres (Figure 2—figure supplement 2, A-middle graph). Therefore, our detailed analysis of the nature and timing of T-SCEs in TRF1 deficient MEFs not only demonstrates an unappreciated role of TRF1 in suppressing HR, but also suggests that single chromatid exchanges, characteristic of conservative DNA synthesis – Break Induced Replication (Roumelioti et al., 2016), are the initial events arising in TRF1-/- MEFs. To further discriminate between suppression of recombination by TRF1 and replication-dependent recombination, we quantified T-SCEs in mouse cells treated with APH. Like for TRF1-depleted telomeres, we also detected an increase in single exchanges in APH-treated MEFs (Figure 2—figure supplement 2, B-right panel). The absence of reciprocal exchanges between telomere chromatids indicates that APH-dependent replication stress does not trigger an HR repair but only BIR, albeit we cannot completely exclude that longer replication stress could lead to HR (Figure 2—figure supplement 2, B-left panel). Overall our data highlights the specific function of TRF1 in suppressing chromatin remodeling, APBs and HR.

Figure 2. Recombination factors are recruited at TRF1 depleted telomeres.

(A) Table listing chromatin remodellers identified. The corresponding number of unique peptide isolated is indicated for each factor of interest. Same as in Figure 1, light to darker colours indicate increasing relative protein abundance. (B) Validation of chromatin remodeller factors by ChIP-dot blot analysis in wt (+GFP) and TRF1-/- (+CRE) conditions using ChIP grade antibodies against chosen factors after chromatin preparation from MEFs. The blot was revealed with a DIG-Tel-C-rich probe. ChIP signals were normalised to DNA input and GFP control. Data are represented as telomeric enrichment of proteins relative to GFP ± SEM of at least three independent biological replicates. P values, two-tailed student t-test (*, p<0.05; **, p<0.01; ****, p<0.0001). (C) Representative image of Immunofluorescence showing co-localisation of Telomeres (red) with PML (green) in MEFs nuclei (DAPI) treated with GFP and CRE. Data from two independent biological replicates are represented as number of Telomeres-PML co-localising foci divided by the total number of PML present per nucleus (n = 300 nuclei) with a violin plot, where the median is underlined in red and quartiles in white. P values, two-tailed student t-test (****, p<0.0001). Source data are provided as a Source Data File. (D) Representative images of the chromosome-oriented CO-FISH assay with denaturation, used to score for telomeric T-SCEs in TRF1F/F MEFs infected with GFP or CRE. Telomeres are labelled with TelPNA-C-rich-Cy3 (red) and TelLNA-G-rich-FAM (green), while chromosomes are counterstained with DAPI (blue). Scale bar, 10 µm. Enlarged intersections show the difference between a chromosome with No T-SCE (top) and a chromosome with T-SCE (bottom). T-SCE images show double T-SCEs (left) and single chromatid events (right). Scale bar, 2 µm. For quantification, T-SCE was considered positive when involved in a reciprocal exchange of telomere signal with its sister chromatid (both telomeres yellow) and for asymmetrical exchanges at single chromatid (one telomere yellow). Data are indicated as % of T-SCE per sister telomere (n = > 3000 chromsome ends) and are represented with a violin plot, where the median is underlined in red and quartiles in white. P value, two-tailed student t-test (****, p<0.0001).

Figure 2—source data 1. Control specificity of proteomic binding (TRF1-/- telo vs TRF1-/- scbl).
Related to Figure 2A.
Figure 2—source data 2. ChIP quantification in TRF1F/F MEFs.
Related to Figure 2B.
Figure 2—source data 3. Quantification of APBs in TRF1F/F MEFs.
Related to Figure 2C.
Figure 2—source data 4. T-SCEs quantification in TRF1F/F MEFs.
Related to Figure 2D.

Figure 2.

Figure 2—figure supplement 1. Validation of telomeric ChIP with ALU probe and effect of APH on telomeric chromatin and APBs.

Figure 2—figure supplement 1.

(A) Control for Figure 2B, dot-blot for validation of chromatin remodellers factor specifically recruited at TRF1 depleted telomeres. The blot was revealed with a DIG-Alu probe (left panel). ChIP signals were normalised to DNA input (top, right panel) and GFP control and data are represented as relative Alu enrichment ± SEM of 3 independent biological replicates. P values, two-tailed student t-test. Source data are provided as a Source Data File. (B) Detection of chromatin remodeler factors by ChIP-dot blot analysis in wt (+DMSO) and Aphidicolin treated cells (+Aph) conditions using ChIP grade antibodies in MEFs chromatin (left panel). The blot was revealed with a DIG-Tel-C-rich probe. ChIP signals were normalised to DNA input (top middle panel) and GFP control. IgG and TRF2 antibodies were used respectively as negative and positive control for the ChIP experiment (top right panel). Data are represented as telomeric enrichment of proteins relative to DMSO ± SEM of 2 independent biological replicates. P values, two-tailed student t-test (**, p<0.01). (C) Representative image of Immunofluorescence showing co-localisation of Telomeres (red) with PML (green) in MEFs nuclei (DAPI) treated with DMSO or Aphidicolin. Data are represented as number of Telomeres-PML co-localising foci divided by the total number of PML present per nucleus (n > 100 nuclei) and three independent biological replicates are shown in a violin plot, where the median is underlined in red and quartiles in white (left graph). Number of total PML foci per nucleus from three independent biological replicates are shown in a violin plot, where the median is underlined in red and quartiles in white (right graph). P values, two-tailed student t-test (*, p<0.05; ****, p<0.0001). Source data are provided as a Source Data File.
Figure 2—figure supplement 1—source data 1. Alu probe control for ChIP quantification in TRF1F/F MEFs.
Figure 2—figure supplement 1—source data 2. ChIP quantification in MEFs treated with APH.
Figure 2—figure supplement 1—source data 3. Quantification of APBs in MEFs treated with APH.
Figure 2—figure supplement 2. TRF1 loss and APH replication stress induce different types of telomeric recombination.

Figure 2—figure supplement 2.

(A) Time course quantification of the different classes of T-SCEs using denaturing CO-FISH. TRF1F/F MEFs were collected 4 days and 7 days post-infection with CRE-adenovirus or GFP- (control). The different types of exchanges were classified into three different categories: all exchanges (single + double); double exchanges (reciprocal, both chromatids); single exchanges (asymmetrical, single chromatid). Violin plots are representing as % of T-SCE per chromosome ends (n = at least 3000 events were scored), where the median is underlined in red and quartiles in white. P value, two-tailed student t-test (****, p<0.0001; ***, p<0.001; n.s. = non significant). (B) Quantification of telomeric T-SCEs in wt MEFs treated with DMSO or Aphidicolin. Telomeric exchanges are classified as double exchanges (reciprocal, both chromatids-left graph) and single exchanges (asymmetrical, single chromatid-right graph). Violin plots represent % of T-SCE per chromosome ends (n = at least 1500 events were scored), where the median is underlined in red and quartiles in white. P value, two-tailed student t-test (*, p<0.05).
Figure 2—figure supplement 2—source data 1. T-SCEs quantification in TRF1F/F MEFs.
Figure 2—figure supplement 2—source data 2. T-SCEs quantification of MEFs treated with APH.

TRF1 depletion causes TERRAs upregulation in mouse cells

Since depleting telomeres of TRF1 induces chromatin remodelling, formation of APBs and increase of HR, we next decided to revisit the effect of TRF1 on TERRA molecules, which are proposed to regulate telomere recombination (Yu et al., 2014). Previous studies have reported in-vivo interactions between TRF1 and TERRA (Deng et al., 2009) and also a possible transcriptional regulation by TRF1 through a mechanism involving RNA polymerase II - TRF1 interaction (Schoeftner and Blasco, 2008). However, the role of TRF1 regulating telomere transcription appears complex since contrasting results have been reported by different groups in both human and mouse cell lines (Lee et al., 2018; Schoeftner and Blasco, 2008; Sfeir et al., 2009). We performed both RNA dot-blot and Northern-blot analyses showing a significant increase in TERRA molecules upon loss of TRF1 in immortalised MEFs, 7 days after transduction (Figure 3A–B) but also at earlier time point (day 4) and in primary MEFs (Figure 3—figure supplements 1, A–B–C). Collectively, we identify an increase in TERRA molecules upon TRF1 removal from telomeres, which suggests a TRF1 function in suppressing mouse TERRAs. Particularly, we noticed that these TERRAs have high molecular weight and can only be detected when an alkaline treatment is performed during Northern-blotting (Figure 3—figure supplement 1, D). In addition, we carried out TERRA-FISH (Figure 3C) in MEFs deficient for TRF1, confirming a significant increase in numbers and intensity of TERRA foci per nucleus (Figure 3C). To determine whether this phenotype is a direct consequence of replication stress, MEFs were treated with low doses of APH and TERRA analysis was carried out by RNA dot-blot and Northern blot. Similar to TRF1 depleted cells, APH-treated MEFs exhibited a significant increase in TERRAs (Figure 3—figure supplement 1, E–F). Taken together, these results suggest that TRF1-dependent replication stress enhances telomere transcription or TERRAs stability.

Figure 3. TRF1 depletion causes TERRAs upregulation.

(A) RNA dot blot analysis in wt and TRF1 deleted MEFs. The blot was revealed with a DIG-Tel-C-rich probe or 18 s rRNA as a control. TERRA signals were normalised to 18 s rRNA and GFP control ± SEM of at least three independent biological replicates. P values, two-tailed student t-test (****, p<0.0001). (B) TERRA detection by Northern blotting upon TRF1 deletion. The blot was revealed with a DIG-Tel-C-rich probe (upper part). Ethidium bromide (EtBr) staining (bottom) of rRNAs was used as loading control. TERRA signals were normalized to 28 s rRNA signal from EtBr staining ± SEM of 2 independent biological replicates. P values, two-tailed student t-test (**, p<0.01). (C) Representative images of TERRA-FISH experiment (top panel) showing the difference between cells stained with TERRA (red), negative control with RNAse A treatment and positive control after denaturation. TERRA-FISH quantification (bottom panel) in wt (+GFP) and TRF1-/- (+CRE) conditions. Violin plots are representing the number of TERRA foci (left) and TERRA intensity (right) (n = 250) per nucleus, where the median is underlined in red and quartiles in white, two-tailed student t-test (****, p<0.0001); Mann-Whitney test used for TERRA intensity quantification (*, p<0.05).

Figure 3—source data 1. Quantification of Telomeric RNA molecules by dot-blot in TRF1F/F MEFs.
Related to Figure 3A.
Figure 3—source data 2. Quantification of TERRAs by Northern.
Related to Figure 3B.
elife-49817-fig3-data2.xlsx (761.2KB, xlsx)
Figure 3—source data 3. Quantification of number of TERRA foci.
Related to Figure 3C.

Figure 3.

Figure 3—figure supplement 1. TRF1 deletion and APH replication stress cause increased TERRA levels in immortalised MEFs (day4) and also in primary MEFs (day 6).

Figure 3—figure supplement 1.

(A) Western blotting showing protein expression in wt and TRF1 deficient primary MEFs (P4) 6 days post-infection with GFP- or CRE-Adenovirus (left panel) and in SV40-immortalised MEFs, 4 days post-infection (right panel). (B) RNA dot-blot analysis upon TRF1 deletion showing increased TERRA signals in CRE-infected conditions compared to control GFP-. The blot was revealed with a DIG-Tel-C-rich probe or 18 s rRNA as a control. (C) Quantification of B. Data are shown as TERRA signal relative to GFP condition ± SEM of 4 independent biological replicates. P values, two-tailed student t-test (*, p<0.05; ****, p<0.0001) (D) TERRA detection by Northern blotting upon TRF1 deletion showing increased High Molecular Weights (HMW) RNA molecules upon alkaline treatment (left blot). In native conditions, HMW-TERRAs are not detected and no significative difference is observed for low molecular weight species (right blot). The blots were revealed with a DIG-Tel-C-rich probe (upper part). Ethidium bromide (EtBr) staining (bottom) of rRNAs was used as loading control. Source data are provided as a Source Data File. (E) RNA dot-blot analysis in wt MEFs cells upon Aphidicolin treatment showing increased TERRA signals compared to control DMSO. The blot was revealed with a DIG-Tel-C-rich probe or 18 s rRNA as a control (top panel). Quantification of Data are shown as TERRA signal relative to DMSO condition ± SEM of 4 independent biological replicates (bottom panel). P values, two-tailed student t-test (*, p<0.05). (F) TERRA detection by Northern blotting upon Aphidicolin treatment showing increased High Molecular Weights (HMW) RNA molecules upon alkaline treatment. The blot was revealed with a DIG-Tel-C-rich probe (upper part). Ethidium bromide (EtBr) staining (bottom) of rRNAs was used as loading control. Source data are provided as a Source Data File.
Figure 3—figure supplement 1—source data 1. WB of TRF1F/F primary MEFs and immortalized after 4 days of CRE.
Figure 3—figure supplement 1—source data 2. Telomeric RNA molecules by dot-blot in primary TRF1F/F MEFs and immortalized after 4 days of CRE.
Figure 3—figure supplement 1—source data 3. Quantification of Telomeric RNA molecules by dot-blot in primary TRF1F/F MEFs and immortalized after 4 days of CRE.
Figure 3—figure supplement 1—source data 4. TERRAs by Northern in TRF1F/F MEFs.
Figure 3—figure supplement 1—source data 5. Quantification of Telomeric RNA molecules by dot-blot in wt MEFs treated with APH.
Figure 3—figure supplement 1—source data 6. TERRAs by Northern in wt MEFs treated with APH.
Figure 3—figure supplement 2. TRF1 deficient MEFs present normal telomere distribution, telomerase activity and no c-circles.

Figure 3—figure supplement 2.

(A) Terminal Restriction Fragments (TRF) blot showing no telomere length heterogeneity upon TRF1 deletion (+CRE, 7 days post-infection) compared to control TRF1F/F +GFP MEFs. The blot was revealed with a DIG-Tel-C-rich probe (right). Ethidium bromide (EtBr) staining (left) is used as loading control. (B) Quantification of telomerase activity levels by TRAP assay showing no changes in telomerase activity after TRF1 deletion in MEFs. Values are normalised to the control HT1080-ST cells (100%) and are represented as mean ± SEM of 4 independent biological replicates. (C) C-circle assay showing no c-circle formation upon TRF1 deletion (+CRE, 7 days post-infection) compared to control TRF1F/F +GFP MEFs. Phi polymerase amplification products were spotted on the membrane and revealed using DIG-TelC probe. TRF1F/F MEFs treated with aphidicolin (APH) are used as negative control for telomere fragility not inducing C-circles, while U2OS, ALT positive cell line, is used as positive control. Source data are provided as a Source Data File.
Figure 3—figure supplement 2—source data 1. Telomere length by Southern in TRF1F/F MEFs.
Figure 3—figure supplement 2—source data 2. Telomerase activity by TRAP in TRF1F/F MEFs.
Figure 3—figure supplement 2—source data 3. c-circle amplification assay in TRF1F/F MEFs and U2OS (+ctl).

mTRF1-dependent APBs formation and BIR are conserved in human cells

The presence of APBs, BIR, HR and TERRAs, in TRF1-/- MEFs indicates some similarities with ALT telomeres. However, the absence of telomere heterogeneity, c-circle formation and still presence of telomerase activity (Figure 3—figure supplements 2, A–B–C) also suggest that this ALT-like phenotype is not complete. To test whether the function of TRF1 in suppressing these ALT-like features is conserved in human cells, we used small RNA interference against TRF1 in HT1080-ST cells (long telomeres), performing all the analysis 6 days post-transfection (Figure 4A). TRF1-depleted HT1080-ST cells present a modest but significant increase in APBs formation (Figure 4B). This phenotype appears to be milder as compared to TRF1-/- MEFs, probably because HT1080/ST present higher levels of APBs compared to other human (Pickett et al., 2009) or mouse cells (Figure 2C). We conclude that TRF1 function is somewhat maintained between the two species. To assess the human TRF1 function in suppressing HR and BIR, we measured sister chromatid exchanges at telomeres in HT1080-ST depleted for TRF1 (Figure 4C). We observed a significant increase in single exchanges (Figure 4C-right panel) however, we could not detect double exchanges in cells transfected with TRF1 siRNA compared to the ctl (Figure 4C-left panel). Finally, TERRA expression was analysed by DNA dot blot and no differences were observed between ctr and TRF1 depleted cells (Figure 4—figure supplement 1, A). To evaluate whether long term depletion of TRF1 in human cells would cause any increase in TERRA expression, as observed in TRF1-/- MEFs, we used a doxycycline inducible TRF1 CRISPR/Cas9 HeLa cell line (Figure 4—figure supplement 1, B) (Kim et al., 2017). However, even 15 days after hTRF1 deletion, no significant increase in TERRAs was detected. Human TRF1 KO cells did not show any growing defects after 15 days in culture, which is remarkably different from TRF1 deficient MEFs that fail to proliferate due to a rapid induction of senescence (Karlseder et al., 2003; Martínez et al., 2009).

Figure 4. Human TRF1 suppresses APBs formation and BIR.

(A) Western blotting showing expression of TRF1 and Actin (loading control) proteins in human HT1080-ST cell line after depletion of TRF1 with siRNAs (6 days post transfection). sictr is used as negative control for transfection. (B) Representative image of Immunofluorescence showing co-localisation of Telomeres (red) with PML (green) in HT1080-ST nuclei (DAPI) transfected with sictr or siTRF1. Data are represented as number of Telomeres-PML co-localising foci divided by the total number of PML present per nucleus (n = 150 nuclei) and are shown as a violin plot, where the median is underlined in red and quartiles in white. P values, two-tailed student t-test (*, p<0.05). Source data are provided as a Source Data File. (C) Quantification of telomeric T-SCEs in HT1080-ST transfected with sictr or siTRF1. Telomeric exchanges are classified as double exchanges (reciprocal, both chromatids-left graph) and single exchanges (asymmetrical, single chromatid-right graph). Violin plots represent % of T-SCE per chromosome ends (n = at least 1500 events were scored), where the median is underlined in red and quartiles in white. P value, two-tailed student t-test (**, p<0.01).

Figure 4—source data 1. KD of TRF1 in HT1080-ST cells.
Related to Figure 4A.
Figure 4—source data 2. Quantification of APBs in HT1080-ST TRF1 KD.
Related to Figure 4B.
Figure 4—source data 3. T-SCEs quantification in HT1080-ST TRF1 KD.
Related to Figure 4C.

Figure 4.

Figure 4—figure supplement 1. Human TRF1 does not influence TERRAs.

Figure 4—figure supplement 1.

(A) RNA dot-blot analysis in HT1080-ST cells upon sictr or siTRF1 transfection. The blot was revealed with a DIG-Tel-C-rich probe or 18 s rRNA as a control (top panel). Quantification of Data are shown as TERRA signal relative to sictr condition ± SEM of 2 independent biological replicates (bottom panel). P values, two-tailed student t-test. (B) Western blotting (left panel) showing expression of TRF1 and Actin (loading control) proteins in human Hela cell line after deletion of TRF1 (15 days post treatment with doxycycline). -dox is used as negative control. RNA dot-blot analysis in HeLa cells upon deletion of TRF1 (+Dox). The blot was revealed with a DIG-Tel-C-rich probe or 18 s rRNA as a control (top panel). Quantification of Data are shown as TERRA signal relative to -Dox condition ± SEM of 2 independent biological replicates (bottom panel). P values, two-tailed student t-test (*, p<0.05).
Figure 4—figure supplement 1—source data 1. Quantification of Telomeric RNA molecules by dot-blot in HT1080-ST TRF1 KD.
Figure 4—figure supplement 1—source data 2. KO efficiency and quantification of Telomeric RNA molecules by dot-blot in Dox inducible HeLa CRISPR/Cas9 system.

In conclusion, some of TRF1 functions are conserved between mouse and human. For both species, TRF1 suppresses telomere fragility and therefore is essential to facilitate DNA replication through telomeric repeats (Lee et al., 2018; Sfeir et al., 2009). We now show that like for mouse TRF1, its human homolog is essential to suppress APBs formation and BIR, which is likely responsible for the rescue of stalled/collapsed telomeric forks.

TRF1 suppresses mitotic DNA synthesis at telomeres

Since the denaturing CO-FISH experiments in TRF1 deficient cells identified single chromatid exchanges that are proposed to be reminiscent of BIR events, an HR alternative pathway required in G2-M phase (Roumelioti et al., 2016), we tested whether TRF1 depleted telomeres trigger non S-phase DNA synthesis. We performed a pulse with 5-bromo-2-deoxyuridine (BrdU) for 2 hr (Figure 5A) before carrying out BrdU immunofluorescence at telomeres in interphase cells (Figure 5B–C). Only non S-phase cells were counted in this experiment, based on the formation of clear BrdU foci (Dilley et al., 2016; Nakamura et al., 1986) (Figure 5B). TRF1-/- MEFs display elevated BrdU incorporation at telomeres, showing two-times more telomere synthesis compared to control cells (Figure 5C). To investigate DNA synthesis happening exclusively in mitosis, so-called MiDAS (Minocherhomji et al., 2015), we performed a similar experiment in metaphases. After incubating wt and TRF1 deficient MEFs with 5-ethynyl-2-deoxyuridine (EdU) and colcemid for 1 hr, mitotic cells were collected to analyse EdU incorporation on metaphase chromosomes (Figure 5A). We scored for telomeric and non-telomeric EdU foci (mitotic DNA synthesis) and found that CRE induced cells had a significant increase in telomeric mitotic DNA synthesis compared to the GFP control cells (Figure 5D). This result confirms that TRF1 depleted telomeres present an increased level of non-S-phase DNA synthesis, similar to what is observed in ALT cells. In addition, analysis of EdU incorporation in metaphase spreads allowed us to distinguish between conservative BIR associated DNA synthesis and HR semi-conservative DNA synthesis (Min et al., 2017). In the first case, EdU would be labelled on a single chromatid (Figure 5E upper panel), while in the latter, EdU would localise to both chromatids (Figure 5E bottom panel). Thus, to assess the mechanism of DNA synthesis in TRF1 deleted cells, the pattern of EdU incorporation on metaphase chromosomes was further investigated (Figure 5F). Non-telomeric (upper panel) and telomeric (middle panel) EdU foci formed mainly on a single chromatid. In fact, 72% of the mitotic DNA synthesis at non-telomeric sites localised to a single chromatid, while the remaining 28% of the signal was present at both chromatids (Figure 5F, upper panel). This result is even more striking when EdU signal was restricted to telomeres, with almost all the co-localisation being present at single chromatids (95%). These observations suggest that TRF1 is crucial for the suppression of mitotic DNA synthesis mediated by BIR at telomeres.

Figure 5. Deletion of TRF1 induces mitotic DNA synthesis at telomeres.

Figure 5.

(A) Schematic overview of the experimental timeline. TRF1F/F MEFs cells were infected twice (day 0 and 3) with adenovirus containing either GFP control or CRE to mediate TRF1 deletion. Prior to collection at day 7, cells were treated with either BrdU (100 µM) for 2 hr or EdU (100 µM) + colcemid for 1 hr, to perform respectively BrdU-Immunofluorescence (IF) or EdU-FISH on metaphases. (B) Representative image of BrdU (red) - TRF2 (green) immunofluorescence showing example of cells in S-phase (upper panel) and non-S-phase (bottom panel). (C) Immunofluorescence showing co-localisation of BrdU (red) with TRF2 (green) in TRF1F/F MEFs nuclei (DAPI, blue) treated with GFP and CRE. Scale bar, 5 µm (denaturing conditions). Data are represented in a violin plot as % of cells in non-S-phase showing BrdU-TRF2 co-localising foci (n = 100 nuclei), where the median is underlined in red and quartiles in white, two-tailed student t-test (****, p<0.0001). (D) Quantification of DNA synthesis using the number of EdU-positive intra-chromosomes or telomeres in TRF1F/F cells infected with GFP and CRE relative to the GFP control (n = 50 metaphases). Data are represented as relative enrichment to the GFP control ± SEM of 3 independent biological replicates. P values, two-tailed student t-test (**, p<0.01). (E) Schematic representation of Break Induced Replication (top part) with single EdU foci at a single chromatid and Homologous recombination (bottom part) with EdU foci at both chromatids. (F) Analysis of DNA synthesis in TRF1 deleted cells. Upper panel: Non-telomeric mitotic DNA synthesis. Representative images showing EdU signal (green) in a single chromatid or in both chromatids. Pie chart representing % of chromosomes having EdU signal at a single chromatid or at both chromatids. Bottom panel: Telomeric mitotic DNA synthesis. Representative images showing EdU signal (green) at telomeres (red) at single or both chromatids. Pie chart representing % of chromosomes having EdU signal at telomeres at a single chromatid or both chromatids. Source data are provided as a Source Data File.

Figure 5—source data 1. Quantification of BrdU-TRF2 co-localisation in S and non-S nuclei.
Related to Figure 5C.
Figure 5—source data 2. Quantification of Mitosis DNA synthesis in TRF1F/F MEFs and at telomeres.
Related to Figure 5D and F.

Mitotic DNA synthesis at replication stressed telomeres is POLD3 dependent

BIR is a recombination dependent process reinitiating DNA replication when one end of a chromosome shares homology with the template DNA, leading to conservative DNA synthesis, which is dependent on RAD52 and POLD3 (pol32 homolog in yeast) (Bhowmick et al., 2016; Sotiriou et al., 2016). ALT telomeres have recently been reported to be elongated by BIR, in a POLD3 and SMC5-dependent manner (Dilley et al., 2016; Min et al., 2017; Potts et al., 2006). Since the SMC5/6 complex was exclusively enriched in PICh purified TRF1 depleted telomeres (Figure 2A), we further investigated the role of POLD3 and SMC5 in BIR DNA synthesis observed in TRF1-/- MEFs. We generated TRF1 F/F cells deficient in SMC5 or POLD3 using specific shRNAs. Upon infection with GFP or CRE adenovirus, we produced respectively single or double deletion TRF1-SMC5 or TRF1-POLD3 cell lines. Loss of SMC5 and TRF1 expression were confirmed by immunoblotting (Figure 6A–B), while mRNA levels of POLD3 were analysed by RT-QPCR (Figure 6C). We only noticed a slight decrease in population doublings in the double mutants, while all cell lines were still able to properly divide and incorporate EdU (Figure 6—figure supplement 1, A–B). Thus, we carried out EdU-FISH in these cells to check for the presence of BIR (Figure 6D). We found that the enrichment of DNA synthesis at telomeres in TRF1 deleted cells was suppressed in the double mutant TRF1-POLD3, while the double mutant TRF1-SMC5 revealed similar telomeric DNA synthesis when compared to the single TRF1 mutant (Figure 6E). First, these results confirm that BIR is the molecular mechanism taking place at TRF1 depleted telomeres. Second, SMC5 appears to be dispensable for BIR dependent DNA synthesis at these replication-stressed chromosome ends.

Figure 6. POLD3 but not SMC5 regulates mitotic DNA synthesis at TRF1 deleted telomeres.

(A) Western blotting showing expression of SMC5, TRF1 and Actin (loading control) proteins in TRF1F/F MEFs after infection with GFP or CRE-Adenovirus and deletion of SMC5 by shRNA. shGAPDH is used as negative control. (B) Quantification of the knock-out and knock-down shown in A. Graph shows protein signal quantification relative to shGAPDH in +GFP control cells, data are represented as mean ± SEM of 3 independent biological replicates. (C) Quantification of POLD3 mRNA levels relative to GAPDH control. Data are represented as mean ± SEM of 3 independent biological replicates. (D) Representative images of 6 different genotypes generated in the above description. Metaphases show EdU (green), telomeres labelled with TelPNA-C-rich-Cy3 (red) and chromosomes counterstained with DAPI (blue). Scale bar, 10 µm. (E) Quantification of mitotic DNA synthesis at telomeres (single chromatid) in TRF1F/F MEFs infected with shGAPDH control (GFP or CRE), shSMC5 (GFP or CRE) and shPOLD3 (GFP or CRE). Data are represented (n = 50 metaphases) as number of EdU positive telomeres per metaphase with a violin plot, where the median is underlined in red and quartiles in white. One-way ANOVA multiple comparisons (**, p<0.01; ****, p<0.0001) relative to shGAPDH+GFP sample. Source data are provided as a Source Data File.

Figure 6—source data 1. WB and Quantification of SMC5 knock-down efficiency in TRF1F/F MEFs.
Related to Figure 6A and B.
Figure 6—source data 2. POLD3 mRNA levels after KD in TRF1F/F MEFs.
Related to Figure 6C.
Figure 6—source data 3. Quantification of Mitosis DNA synthesis at telomeres in TRF1F/F MEFs with and without POLD3 and SMC5.
Related to Figure 6D and E.

Figure 6.

Figure 6—figure supplement 1. Cell proliferation and EdU incorporation are not affected in TRF1, TRF1-SMC5 and TRF1-POLD3 mutants.

Figure 6—figure supplement 1.

(A) Growth curves showing cell proliferation in TRF1F/F MEFs infected with shGAPDH control (GFP or CRE), shSMC5 (GFP or CRE) and shPOLD3 (GFP or CRE). Population doublings were calculated for each condition. (B) Representative images of IF showing EdU(green) incorporation in MEFs nuclei (DAPI). Quantification of cells (as %) incorporating EdU using IF-staining (n = 250). Cells positive for EdU staining were classified as in S-Phase, while cells negatively stained for EdU were scored as in non-S phase, for the same genetic backgrounds as in A. Source data are provided as a Source Data File.
Figure 6—figure supplement 1—source data 1. Population doublings in TRF1F/F MEFs with and without POLD3 and SMC5.
Figure 6—figure supplement 1—source data 2. Number of S- and non-S phase in TRF1F/F MEFs with and without POLD3 and SMC5.
Figure 6—figure supplement 2. SMC5 and POLD3 are dispensable for TRF1 dependent telomere fragility.

Figure 6—figure supplement 2.

(A) Representative images of metaphases stained with TelPNA-Cy3 probe (red) and DAPI (blue) from TRF1F/F MEFs infected with shGAPDH control (GFP or CRE), shSMC5 (GFP or CRE) and shPOLD3 (GFP or CRE). Scale bar, 10 µm. (B) Enlarged image showing telomere fragility. (C) Quantification of A-B. Data are indicated as % telomere fragility per chromosome. Data from three independent biological replicates are indicated in a violin plot, where the median is underlined in red and quartiles in white. P value, two-tailed student t-test (****, p<0.0001). Source data are provided as a Source Data File.
Figure 6—figure supplement 2—source data 1. Fragile telomeres in TRF1F/F MEFs with and without POLD3 and SMC5.

SMC5 and POLD3 are required for APBs formation and recombination at TRF1 deficient telomeres

We further examined whether POLD3 and SMC5 could be responsible not only for the BIR dependent DNA synthesis but also for the other ALT-like phenotypes observed at TRF1 deficient telomeres.

Since TRF1 is well known to suppress telomere fragility or MTS (Sfeir et al., 2009) (Martínez et al., 2009), we first investigated the role of POLD3 and SMC5 in the induction or maintenance of this telomere replication stress in the double mutants (Figure 6—figure supplement 2, A–B). As previously reported, TRF1 depleted telomeres present approximately 20% of fragile telomeres per chromosomes (Figure 6—figure supplement 2, C). We could not detect any changes in the frequency of telomere fragility in TRF1-POLD3 nor TRF1-SMC5 mutants (Figure 6—figure supplement 2, C) suggesting that neither POLD3 nor SMC5 are involved in the mechanism that gives rise to telomere fragility. As APBs were increased in TRF1 deleted cells (Figure 2C), we investigated the roles of POLD3 and SMC5 in the formation of these specialised bodies. A significant reduction in number of cells having co-localising PML-telomere foci was detected in the double mutant cells TRF1-POLD3 and TRF1-SMC5 (Figure 7A) suggesting that POLD3 and SMC5 are necessary for the formation of these recombination machinery loci. We next explored the involvement of these two factors in HR by scoring for T-SCE (Figure 7B), discriminating also between the two categories of T-SCEs (single or double exchanges) in the analysis of the double mutants TRF1-SMC5 and TRF1-POLD3. We found that both types of exchanges are dependent on SMC5 and POLD3 (Figure 7—figure supplement 1). Finally, we assessed TERRA expression levels in the double mutants. Surprisingly, only the absence of POLD3 was able to rescue the increase in TERRA levels detected in TRF1 deficient cells, while the SMC5 single mutant increased TERRA expression (Figure 7C). Collectively, our data indicate that both POLD3 and SMC5 are essential for T-SCE and APBs formation, but only POLD3 is required to maintain increased TERRA levels and BIR observed in TRF1 deficient cells. This suggests that POLD3 and SMC5 have separate roles or act at different stages of the recombination events happening at TRF1 depleted telomeres, advocating also an intriguing connection between TERRA and BIR. We speculate that TERRA could trigger the homology search by stimulating the initial steps of BIR in which POLD3 is involved (Figure 8).

Figure 7. SMC5 and POLD3 are required for induction of recombination at TRF1 deficient telomeres.

(A) APBs formation in TRF1 deleted cells is rescued in double mutants TRF1-SMC5 and TRF1-POLD3. Quantification of APBs formation is represented as number of co-localising PML-telomere foci divided by the total number of PML present per nucleus (n = 300 nuclei analysed) from three independent biological replicates. Data are represented with a violin plot, where the median is underlined in red and quartiles in white. One-way ANOVA multiple comparisons (****, p<0.0001) relative to shGAPDH+GFP sample. (B) Representative images of the chromosome oriented (CO)-FISH assay with denaturation, used to score for telomeric T-SCEs in TRF1F/F MEFs infected with shGAPHH control (GFP or CRE), shSMC5 (GFP or CRE) and shPOLD3 (GFP or CRE). Telomeres are labelled with TelPNA-C-rich-Cy3 (red) and TelLNA-G-rich-FAM (green), while chromosomes are counterstained with DAPI (blue). Scale bar, 10 µm. For quantification T-SCE was considered positive when involved in a reciprocal exchange of telomere signal with its sister chromatid (both telomeres yellow) and for asymmetrical exchanges at single chromatid (one telomere yellow). Data are indicated as % of T-SCE per sister telomere (bottom panel). Data (n = > 2600 chromsome ends) from three independent biological replicates are indicated in a violin plot, where the median is underlined in red and quartiles in white. One-way ANOVA multiple comparisons (****, p<0.0001) relative to shGAPDH+GFP sample. (C) RNA dot blot analysis in TRF1, SMC5, POLD3 single and double mutants. The blot was revealed with a DIG-Tel-C-rich probe or 18 s rRNA as a control. TERRA signals were normalised to 18 s rRNA and GFP control (bottom panel). Data are represented as relative TERRA signal ± SEM of 4 independent biological replicates. P values, two-tailed student t-test (*, p<0.05; ***, p<0.001; n.s. = non significant). Source data are provided as a Source Data File.

Figure 7—source data 1. APBs co-localisations quantification in TRF1F/F MEFs with and without POLD3 and SMC5.
Related to Figure 7A.
Figure 7—source data 2. T-SCEs quantification in TRF1F/F MEFs with and without POLD3 and SMC5.
Related to Figure 7B.
Figure 7—source data 3. Quantification of Telomeric RNA molecules by dot-blot in TRF1F/F MEFs with and without POLD3 and SMC5.
Related to Figure 7C.

Figure 7.

Figure 7—figure supplement 1. SMC5 and POLD3 are required for TRF1 dependent telomere recombination.

Figure 7—figure supplement 1.

Quantification of telomeric T-SCEs in TRF1F/F MEFs infected with shGAPDH control (GFP or CRE), shSMC5 (GFP or CRE) and shPOLD3 (GFP or CRE). Telomeric exchanges are classified as double exchanges (reciprocal, both chromatids-left graph) and single exchanges (asymmetrical, single chromatid-right graph). Violin plots represent % of T-SCE per chromosome ends (n = at least 2500 events were scored), where the median is underlined in red and quartiles in white. P value, two-tailed student t-test (*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001).
Figure 7—figure supplement 1—source data 1. T-SCEs quantification in TRF1F/F MEFs with and without POLD3 and SMC5.
Related to Figure 7—figure supplement 1A. Accession code for the proteomic data will be made available before publication on public repository PRIDE.

Figure 8. Model describing TRF1 as a negative regulator of telomeric transcription (TERRAs), APBs formation, telomeric recombination via PolD3-BIR dependent pathway.

Figure 8.

Replicative stress induced by TRF1 deletion alters the chromatin status of these telomeres. Recruitment of chromatin remodellers/HR factors, TERRA accumulation and telomere fragility are observed. The SMC5/6 complex and polymerase POLD3 are among the factors recruited at replicative-stressed telomeres, representing the key players for APBs formation and telomere recombination, particularly BIR-mechanism. We propose that increased TERRAs molecules at telomeres could lead to increased R-loops, which are bypassed by POLD3 dependent BIR to resolve fork progression hindrance.

Discussion

Faithful DNA replication of genetic information is essential for the maintenance of genome stability and integrity. Specific genomic loci, including fragile sites and telomeres, represent major obstacles to DNA replication progression and/or completion. Fragile sites have the propensity to form visible gaps or breaks on chromosome in metaphase spreads of cell lines from patients having fragile X-syndrome or Huntington’s disease (reviewed in Minocherhomji and Hickson, 2014; Minocherhomji et al., 2015). It is well documented that CFS expression is exacerbated in cells grown under low to mild replication stress, for example upon inhibition of DNA polymerase with APH (Minocherhomji and Hickson, 2014; Minocherhomji et al., 2015). Fragile sites are hotspots for deletions, chromosome rearrangements and are associated with an increased frequency of homologous recombination (Glover and Stein, 1987). Over the last decade, telomeres have been identified as APH induced fragile sites displaying the standard phenotype of multiple spatially distinct telomere foci (MTS or telomere fragility) on metaphase spreads (Martínez et al., 2009; Sfeir et al., 2009). Various factors suppress MTS and thereby facilitate DNA replication at telomeres; including (Zaaijer et al., 2016) the shelterin protein TRF1 (Martínez et al., 2009; Sfeir et al., 2009), the DNA helicases RTEL1 (Vannier et al., 2012), BLM and WRN (Barefield and Karlseder, 2012), Topoisomerase TopoIIa (d'Alcontres et al., 2014) and Rif1 (Zaaijer et al., 2016). High levels of DNA damage and telomere fragility are characteristics of ALT cells (Cesare et al., 2009) (Min et al., 2017), presenting several DNA repair and damage factors in APBs (Draskovic et al., 2009; Wu et al., 2000; Yeager et al., 1999), indication of elevated telomeric stress in these cells. Therefore, it has been hypothesized that ALT mechanism arises from persistent replication stress, which can be resolved by the initial collapse of the replication fork, subsequently offering substrates for HR repair mechanisms dependent on homology search and telomere synthesis as reported with BIR pathway (Dilley et al., 2016).

In this study, we report that replication stress generated at TRF1 depleted telomeres in telomerase positive MEFs is associated with the recruitment of ALT signature factors including PML, subunits of the NuRD complex, BRCA1 and SMC5/6 complex. We suggest that the formation of permissive telomeric chromatin enables transcription of telomeric sequences into TERRAs and increases recombination as measured by T-SCEs, in a POLD3 and SMC5/POLD3 dependent manner, respectively. Moreover, we detect mitotic DNA synthesis at TRF1 depleted telomeres, which is dependent on POLD3 but not SMC5. Comparison analysis with APH-treated MEFs highlighted the unappreciated role of mouse TRF1 in suppressing telomere chromatin re-organisation, which we propose to contribute to HR-dependent telomere-sister chromatid exchanges. Herein, we showed that telomere replication stress induced by TRF1 deletion generates additional telomere responses (APBs, Chromatin remodeling, HR) compared to APH treated MEFs. We propose this is imputed to the function of TRF1 in stabilising telomere chromatin. Both mouse and human TRF1 suppresses telomere fragility and therefore is essential to facilitate DNA replication through telomeric repeats (Lee et al., 2018; Sfeir et al., 2009). We now show that like for mouse TRF1, its human homolog is essential to suppress APBs formation and BIR, that is POLD3 dependent in mouse and likely to contribute to the repair of stalled/collapsed telomeric forks.

Mouse TRF1 is essential for cell proliferation and to counteract TERRAs expression/stability and activation of HR, while it seems dispensable in HT1080-ST and HeLa cells. This could be explained by the difference in chromatin composition between the two species, indeed human telomeres display less abundant repressive marks compared to mouse chromosome ends (García-Cao et al., 2004; O'Sullivan et al., 2010; Rosenfeld et al., 2009). Moreover, mouse and human TERRAs have different origins. The main source of human TERRA molecules is from Human 20q subtelomere (Montero et al., 2016) however, other subtelomeres might contribute to local regulation and therefore control both cis and trans regulations (Tutton et al., 2016Feretzaki et al., 2019). On the other hand, mouse TERRAs primary origin is more controversial with reports proposing Chr18 subtelomere as the principal source in MEFs (de Silanes et al., 2014), while recent literature hints to the subtelomeric regions of ChrX and ChrY (Chu et al., 2017). These PAR-TERRA would be more abundant and involved in trans regulation on the other chromosome ends.

Telomere transcription appears to be differently regulated in human and mouse cells and it is tempting to speculate that the difference in chromatin composition between the two species is essential for different transcription regulations. Therefore, it is plausible that human and mouse telomeres bear different accessibility to HR factors due to the distinct heterochromatin properties, that will undoubtedly be an interesting question to address in the future.

We suggest that chromatin remodelling factors such as NuRD-ZNF827 are recruited to mouse TRF1 deficient telomeres to counteract the shelterin instability. This may be explained by analogy with ALT telomeres where telomeric DNA sequence is interspersed with variant repeats (Conomos et al., 2012; Marzec et al., 2015), which are suggested to cause displacement of shelterin proteins (Conomos et al., 2013), thus increasing replication stress and DDR. In this scenario, nuclear receptors bind the interspersed variant repeats and recruit several chromatin remodelling factors including the NuRD complex, which can further alter the telomere architecture by increasing telomere compaction (Conomos et al., 2014); perhaps a transient state before stimulating telomere associations and generating more ‘open’ recombination permissive conditions at telomeres. In line with our findings, repressive chromatin at DSBs has been proposed to facilitate homology search and promote recruitment of HR proteins like BRCA1 (Khurana et al., 2014). In addition to BRCA1, we have identified through PICh analysis the SMC5/6 complex specifically recruited at TRF1 deficient telomeres. We demonstrate that this complex plays the same role at replication induced telomeres as in ALT cells, targeting telomeres to PML bodies (APBs) and facilitating telomeric HR at these sites (Potts et al., 2006), since double mutant SMC5-TRF1 disrupts formation of APBs and reduces T-SCEs events. However, we were unable to fully induce ALT in TRF1 deficient MEFs, as they display neither C-circles nor heterogeneity in telomere length and telomerase is still active. The latter could act as a stabiliser of telomeric DNA ends generated during fork restart (Tong et al., 2015), similarly to what happens in RTEL1-/- MEFs (Margalef et al., 2018) and in human RTEL1 deficient cells with long telomeres (Porreca et al., 2018).

Persistent DNA damage in ALT cells is suggested to originate from telomeric replication stress, which is proposed to be resolved by BIR in a POLD3 dependent manner (Dilley et al., 2016; Min et al., 2017; Roumelioti et al., 2016). Our results show that TRF1 is a major suppressor of telomeric replication stress and consequently of POLD3 dependent BIR. TRF1 deficient telomeres present slower movement of S-phase replication forks, measured by molecular combing (Sfeir et al., 2009). The slower replication rates at telomeres is proposed to be a consequence of the hindrance of the replication forks by DNA secondary structures, including formation of G-quadruplexes on the lagging strand template or RNA-DNA hybrids. In the absence of TRF1, BLM is unable to be recruited to replicated telomeres and to open DNA secondary structures (Lee et al., 2018; Zimmermann et al., 2014). Based on our results, we propose that in the absence of TRF1, POLD3 dependent BIR bypasses the stalled replication fork during G2/M phase.

Recent studies identified BIR as a mechanism to bypass RNA-DNA hybrids in a Rad52 and Pol32 dependent manner in yeast (Amon and Koshland, 2016; Neil et al., 2018). This mechanism is also conserved in human cells where POLD3 is necessary for the restart of stalled replication forks at RNA-DNA hybrids (Tumini et al., 2016). Altogether, we propose that increased TERRAs levels at TRF1 depleted telomeres could form RNA-DNA hybrids that are bypassed by POLD3 dependent BIR (Figure 8). This is in agreement with recent findings showing that TRF1 suppresses R-loop formation mediated by TRF2 (Lee et al., 2018). In contrast to Pold3, SMC5 acts as inhibitor of TERRA accumulation, as its absence is causing a significant increase in TERRA levels. This result is reminiscent of the role of yeast Smc5 in facilitating the resolution of toxic recombination intermediates at RNA-DNA hybrids generated by the helicase Mph1 (Chen et al., 2009; Lafuente-Barquero et al., 2017). We also describe a role of SMC5 in promoting T-SCEs, but not MiDAS formation (in contrast to PolD3), in the absence of TRF1. These results are indicating an exclusive function of SMC5 in HR at replicative-stressed telomeres, perhaps ensuring the right balance between accumulation and removal of HR-dependent intermediates formed during DNA repair (Aragón, 2018). On the other hand, the lack of Smc5 in promoting MiDAS seems in apparent contradiction with a recent observation in ALT cells (Min et al., 2017), where telomeric MiDAS is decreased in SMC5/6-depleted Saos2 cells. We speculate, this difference is due to an imbalance of factors used for ALT maintenance, compared to the early events observed in our conditional system after only few population doublings. Therefore, we cannot rule out a possible role of SMC5/6 in promoting MiDAS at a later stage, similar to the one observed in ALT maintenance.

Along with MUS81 structure specific nuclease, POLD3 and POLD4 subunits of the DNA polymerase delta are essential for CFS expression observed in human cells under replication stress (Minocherhomji et al., 2015; Tumini et al., 2016). To our surprise, TRF1-POLD3 double mutant did not show any suppression of telomere fragility, indicating key differences in the mechanism generating these phenotypes.

In conclusion, our analysis of TRF1 function provides an unappreciated molecular understanding of the level of protection that this shelterin protein offers at telomeres. Surprisingly, we establish that TRF1 ensures telomeric chromatin stability and suppresses the recruitment of chromatin remodellers including NuRD and the formation of APBs, which together promote a HR prone environment. At the same time, TRF1-dependent replication stress is associated with increased TERRAs expression/stability and activation of POLD3-dependent BIR to restart stalled/collapsed telomeric replication forks.

Materials and methods

Key resources table.

Reagent type
(species) or
resource
Designation Source or
reference
Identifiers Additional
information
Cell line (Homo-sapiens) HT1080-ST fibrosarcoma cell line kind gift from J Lingner Cristofari and Lingner, 2006
Cell line (Homo-sapiens) TRF1 CRISPR/Cas9 HeLa cell line kind gift from Z Songyang Kim et al., 2017 Doxycycline-inducible
Cell line (M. musculus) TRF1F/F Mouse Embryonic Fibroblasts Established in Boulton Lab (Crick Institute) Sfeir et al., 2009 RRID:CVCL_UE12
Primary and SV40 immortalised
Transfected construct (human) - in HT1080-ST TERF1 siRNA SMARTpool: ON-TARGETplus Dharmacon/Thermo Fisher Scientific #L-010542-02-0020 100 nM
Transfected construct (human) - in HT1080-ST ctl siRNA ON-TARGETplus Non-targeting Pool Dharmacon #D-001810-10-20 100 nM
Other Nucleofector II/2b Device Lonza #LO AAB-1001 programme X-001.
Commercial assay, kit Nucleofector kit T Lonza #VVCA-1002
Transfected construct (Mouse) pLKO.1-puromycin lentiviral vectors shRNA for mouse SMC5 Sigma sequence: CCCATAATGCTCACGATTAAT in MEFs
Transfected construct (Mouse) pLKO.1-puromycin lentiviral vectors shRNA for mouse POLD3 Sigma Sequence:
GCATATACTCATGTGTGGTTT
in MEFs
Transfected construct (Mouse) pLKO.1-puromycin lentiviral vectors GAPDH Open biosystems Sequence: CTCATTTCCTGGTATGACA in MEFs
Software, algorithm PRISM eight software, Statistical analysis GraphPad
Chemical compound, drug DAPI stain Invitrogen D1306 (1 µg/mL)
Antibody IgG, Rabbit polyclonal Abcam ab37415 For ChIP
2 μg of antibody
Antibody TRF2, Rabbit polyclonal Novus NB110−57130/B2 For ChIP
5 μg of antibody
Antibody BRCA1, Rabbit polyclonal Novus NBP1-45410 For ChIP
5 μg of antibody
Antibody BAZ1b, Rabbit polyclonal Cell Signaling 2152S For ChIP
5 μg of antibody
Antibody TR4, Mouse monoclonal R and D biosystems pp-H0107B-00 For ChIP
5 μg of antibody
Antibody P66a, Rabbit polyclonal Novus NBP1-87359 For ChIP
5 μg of antibody
Antibody MTA1, Rabbit polyclonal Abcam ab71153 For ChIP
5 μg of antibody
Antibody CHD4, Rabbit polyclonal Novus NB100-57521 For ChIP
5 μg of antibody
Antibody ZNF827, Mouse monoclonal Santa Cruz sc514943 For ChIP
5 μg of antibody
Antibody IgG, Rabbit polyclonal Abcam ab37415 For IF (1:1000)
Antibody TRF2, Rabbit polyclonal Novus NB110−57130/B2 For WB (1:1000) and IF (1:250)
Antibody TRF2, Rabbit polyclonal Gift from T de Lange Ref: 1254 For WB (1:1000) and IF (1:250)
Antibody TRF1, Rabbit polyclonal Gift from T de Lange Ref: 1449 For WB (1:1000) and IF (1:250)
Antibody PML, Rabbit polyclonal Gift from Paul Freemont / For IF (1:250)
Antibody SMC5, Rabbit polyclonal Gift from Jo Murray / For WB (1:1000) and IF (1:250)
Antibody Beta-actin, Mouse monoclonal Abcam ab8226 For WB (1:5000)
Antibody BrdU, Mouse monoclonal MBL MI-11–3 For IF (1:500)
Antibody Anti-rabbit Alexa 488 antibody, Donkey polyclonal Thermo, A21206 For IF (1:2000)
Antibody Anti-mouse Ig-HRP, Goat polyclonal DAKO P0447 For WB (1:5000)
Antibody Anti-Rabbit Ig-HRP, Pig polyclonal DAKO P0217 For WB (1:10000)

For all quantification of telomeric phenotypes, masking was used during data analysis.

Cell culture, viral transductions and transfections with siRNAs

TRF1 conditional knock-out MEFs (SV40-immortalised) were described previously (Martínez et al., 2009; Sfeir et al., 2009). Cells were cultured at 37°C in 5%CO2, using DMEM medium supplemented with 10% FCS (Sigma F2442). To achieve TRF1 deletion, cells were infected twice at 72 hr interval with Ad5-CMV-CRE (m.o.i. of 50) and harvested 3 or 4 days after the second infection.

pLKO.1-puromycin lentiviral vectors containing shRNAs for SMC5 (sequence CCCATAATGCTCACGATTAAT, Sigma), POLD3 (GCATATACTCATGTGTGGTTT, Dharmacon) or GAPDH (CTCATTTCCTGGTATGACA, Open biosystems) were introduced by infection of lentivirus-containing supernatant from 293FT cells. Puromycin selection was performed for 3 weeks at 2 µg/ml and several clones were expanded and cultured before screening them for knock-down efficiency.

HT1080-ST human fibrosarcoma cell line was previously described in Cristofari and Lingner (2006) and was a kind gift from J. Lingner. siRNAs transfections were performed in HT1080-ST cells using Cell Line Nucleofector kit T (Lonza #VVCA-1002) according to the manufacturer’s instructions. Briefly, 2 million HT1080-ST cells were transfected using 100 nM of SMARTpool: ON-TARGETplus TERF1 siRNA (Dharmacon #L-010542-02-0020) or ON-TARGETplus Non-targeting Pool (Dharmacon #D-001810-10-20). Transfection experiments were carried out using Nucleofector II/2b Device (Lonza #LO AAB-1001), programme X-001. Cells were harvested, counted and transfected again every 48 hr until final collection at day 6.

Doxycycline-inducible TRF1 CRISPR/Cas9 HeLa cell line was a kind gift from Z. Songyang and were previously described in Kim et al. (2017). Cells were incubated in 1 µg/ml of doxycycline for 15 days and the media containing fresh doxycycline was replaced every 2 days.

HeLa (Dox inducible TRF1 KO-CRISPR/Cas9) from Zhou Songyang (Kim et al., 2017); mycoplasma contamination testing status: negative. MEFs (TRF1F/F) established by Vannier at London Research Institute (now Crick Institute-Boulton Lab) and with cell services, mycoplasma contamination testing status: negative. HT1080 (originally Mao et al., 1993) is a kind gift from Joachim Lingner, mycoplasma contamination testing status: negative.

Aphidicolin treatment

MEFs were treated with 0.4 µM of Aphidicolin (Sigma A0781) for 72 hr before collection and RNA dot blot analysis. For CO-FISH experiments, cells were treated with Aphidicolin for 56 hr before addition of fresh media containing BrdU/C and metaphase collection was performed after 16 hr. In all the experiments performed using Aphidicolin, media containing fresh drug was changed every 24 hr.

Western blot

Cells were scraped in cold PBS, spun down and incubated in lysis buffer (NaCl 40 mM; Tris 25 mM, pH 8; MgCl 2 mM; SDS 0.05%; Benzonase 1 µl/2 ml; Complete protease inhibitor cocktail, EDTA-free, Roche) for 10 min on ice. The lysates were sheared 10 times by forcing it through a 25G needle and left on ice for another 10 min. 35 μg of protein lysates were denatured for 10 min at 95°C after addition of Laemmli buffer 4X (50 mM Tris pH7; 100 mM DTT; 2%SDS; 0.1%bromophenol blue; 10% glycerol), separated on 4–12% Bis-Tris gels (Invitrogen) and transferred onto a nitrocellulose membrane (Amersham Protran 0.2 µm NC). Rabbit anti-TRF1 (gift from Titia de Lange) and rabbit anti-SMC5 (gift from Jo Murray) antibodies were diluted in PBST (PBS1x; 0.1% Tween-20, Sigma-Aldrich) with 5% non-fat milk. For detection of human TRF1, rabbit anti-TRF1 (SantaCruz #sc-6165-R) antibody was used at a final concentration of 0.2 µg/ml diluted in 5% non-fat milk (w/v) in TBS-T. Following incubations with HRP-coupled secondary antibodies signals were visualised using ECL II kit (Pierce) and x-ray film exposure (Amersham Hyperfilm ECL). Beta-actin antibody was used for normalisation (Abcam, ab8226).

Quantitative RT-PCR

RNA extraction was carried out using RNeasy Mini Kit (Qiagen). 500 ng of RNA were subjected to reverse transcription using random hexamer primers and cDNA Synthesis Kit (Roche) according to the manufacturer’s protocol. Quantitative PCR was performed using QuantiTect SYBR Green PCR Master Mix and the following primers: mouse POLD3 with antisense 5’-ACACCAAGTAGGTAACATGCAG-3’ and sense 5’-AAGATCGTGACTTACAAGTGGC-3’ sequences; Mouse Actin with antisense 5’-CCAGTTGGTAACAATGCCATGT-3’ and sense 5’-GGCTGTATTCCCCTCCATCG-3’ sequences; The PCR cycles were as follows: 95°C for 15 min, 95°C for 15 s, 55°C for 30 s, 72°C for 30 s for 44 cycles.

Telomeric chromatin isolation by PICh

PICh was carried out as previously described (Déjardin and Kingston, 2009) using the following 2’Fluoro-RNA probes for hybridisation: Destiobiotin-108 atom tether-UUAGGGUUAGGGUUAGGGUUAGGGt (Telo probe); Destiobiotin-108 atom tether-GAUGUGGAUGUGGAUGUGGAUGUGg (Scramble probe).

Gel and post digestion processing

Gels were processed using a variant of the in-gel digestion procedure as described in Shevchenko et al. (2006). Briefly, gel sections were excised and chopped into uniform cubes, followed by de-staining with 50/50, 50 mM ammonium bicarbonate (AmBic)/acetonitrile(ACN). Gel sections were then dehydrated with 100% ACN followed by the subsequent sequential steps: reduction with 10 mM dithiothreitol (DTT) at 56°C for 30 min in the dark, dehydration, alkylation with 55 mM iodoacetamide (IAM) at RT for 20 min in the dark and dehydration. Gel sections were finally re-hydrated with a 40 mM AmBic, 10% ACN solution containing 500 ng of Trypsin Gold (Promega, V5280) and incubated overnight at 37°C.Recovered gel digest extracts were dried on a speed-vac, reconstituted with 99/1, H2O/ACN + 0.1% FA and de-salted using a standard stage tip procedure using C18 spin tips (Glygen Corp, TT2C18). Dried gel digest peptide extracts solubilised in 25 µl of 0.1% trifluoroacetic acid (TFA) and clarified solution transferred to auto sampler vials for LC-MS analysis.

Mass spectrometry analysis

Peptides were separated using an Ultimate 3000 RSLC nano liquid chromatography system (Thermo Scientific) coupled to a LTQ Velos Orbitrap mass spectrometer (Thermo Scientific) via an EASY-Spray source. 6 μL of sample was loaded in technical duplicates onto a trap column (Acclaim PepMap 100 C18, 100 μm × 2 cm) at 8 μL/min in 2% acetonitrile, 0.1% TFA. Peptides were then eluted on-line to an analytical column (EASY-Spray PepMap C18, 75 μm × 25 cm). Peptides were separated using a linear 120 min gradient, 4–45% of buffer B (composition of buffer B– 80% acetonitrile, 0.1% formic acid). Eluted peptides were analysed by the LTQ Velos operating in positive polarity using a data-dependent acquisition mode. Ions for fragmentation were determined from an initial MS1 survey scan at 15000 resolution (at m/z 200), followed by Ion Trap CID (collisional induced dissociation) of the top 10 most abundant ions. MS1 and MS2 scan AGC targets set to 1e6 and 1e4 for a maximum injection time of 500 ms and 100 ms respectively. A survey scan m/z range of 350–1500 was used, with a normalised collision energy set to 35%, charge state rejection enabled for +one ions and a minimum threshold for triggering fragmentation of 500 counts.

Data analysis

All data files acquired were loaded into MaxQuant (Cox et al., 2014) version 1.6.0.13 analysis software. Raw files were combined into an appropriate experimental design to reflect technical and biological replicates. The LFQ algorithm and match between runs settings were selected. Data were searched against the UniProt Reference Proteome Mus musculus protein database (UP000000589), downloaded on 16th January 2019 from the UniProt website. The database contains 17,002 reviewed (Swiss-Prot) and 37,186 un-reviewed (TrEMBL) protein sequences. MaxQuant also searched the same database with reversed sequences so as to enable a 1% false discovery rate at peptide and protein levels. A built-in database of common protein contaminants was also searched.

Upon completion of the search, the ‘proteingroups.txt’ output file was loaded in Perseus version 1.4.0.2. Contaminant and reverse protein hits were removed. LFQ intensities were log2 transformed. Data were group categorised to ‘Scramble’, ‘Telomere’ or ‘Deletion’. Data were filtered for a minimum of 3 valid LFQ intensity values in at least one group. Missing values (NaN) were imputed from a normal distribution with default values.

FISH and CO-FISH on metaphase spreads

For metaphase spread preparation, cells were incubated for 60 min with 10 ng/ml colcemid (Roche). Cells were harvested, swollen in 75 mM KCl solution for 15 min at 37°C, fixed in ethanol/acetic acid solution (3:1, v/v) and washed three times with the same fixing solution. Suspensions of fixed cells were dropped onto glass slides and dried overnight before performing FISH experiments.

Q-FISH and CO-FISH procedures were performed as previously described (Ourliac-Garnier and Londoño-Vallejo, 2011). Briefly, metaphase spreads were fixed in 4% formaldehyde for 2 min, washed 3 × 5 min in PBS 1x, treated with pepsin (1 mg/ml in 0.05 M citric acid pH 2) for 10 min at 37°C, post-fixed for 2 min, washed and incubated with ethanol series (70%, 80%, 90%, 100%). Hybridising solution containing Cy3-O-O-(CCCTAA)3 probe (PNA bio) in 70% formamide, 10 mM Tris pH 7.4% and 1% blocking reagent (Roche, 11096176001) was applied to each slide, followed by denaturation for 3 min at 80°C on heating block. After 2 hr hybridisation at RT, slides were washed twice 15 min in 70% formamide, 20 mM Tris pH 7.4, followed by three washes of 5 min in 50 mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween-20, dehydrated in successive ethanol baths and air-dried. Slides were mounted in antifade reagent (ProLong Gold, Invitrogen) containing DAPI and images were captured with Zeiss microscope using Carl Zeiss software. Telomeric signals were quantified using the ImageJ software (Fiji).

For CO-FISH, the cells were treated with 10 µM BrdU:BrdC (3:1) for 16 hr, followed by colcemid treatment as above. Prior to hybridisation slides were treated with RNAse A (0.5 µg/ml in PBS) for 10 min at 37°C, incubated with Hoechst (1 µg/ml in 2XSSC) for 10 min at RT, exposed to UV light for 1 hr and treated with ExoIII to degrade the neosynthesised DNA strand containing BrdU/C. Slides were next dehydrated through ethanol series, hybridising solution containing TelG-FAM probe (Exiqon) in 50% formamide, 2XSSC, 1% blocking reagent was applied to each slide, followed by denaturation for 3 min at 80°C on heating block and hybridisation for 2 hr in the dark. Slides were washed 2 × 15 min in 50% formamide, 2XSSC and 3 × 5 min in 50 mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween-20. Finally, slides were dehydrated, incubated with TelC-cy3 probe for 2 hr, followed by the steps described above in the FISH protocol.

Immunofluorescence-FISH

Cells seeded on slides were permeabilised with Triton X-100 buffer (0.5% Triton X-100; 20 mM Tris pH8; 50 mM NaCl; 3 mM MgCl2; 300 mM sucrose) at RT for 5 min and then fixed in 3% formaldehyde/2%sucrose in PBS1X for 15 min at RT and washed three times in PBS1X. After a 10 min permeabilisation step and a wash in PBS1X, nuclei were incubated with blocking solution (10% serum in PBS1X) for 30 min at 37°C and stained with specific primary antibodies: rabbit anti-PML (1/200, a gift from Paul Freemont); rabbit anti-53bp1 dilution (1/400, Bethyl A300-272A). After three washes in PBS1X, nuclei were incubated with secondary donkey anti-rabbit Alexa 488 antibody (1/400, Life Technologies) for 40 min at 37°C, washed three times in PBS1X, post fixed 10 min and hybridised with TelC-cy3 PNA probe as described in FISH protocol.

EdU labeling and staining were performed as previously reported (Minocherhomji et al., 2015). Briefly, cells were incubated 1 hr with EdU (100 µM) and colcemid (10 ng/ml), followed by metaphase spread preparation. For EdU staining, the steps of fixation, pepsin treatment and dehydration in ethanol serial dilutions were carried out as in FISH protocol, followed by Click IT assay using EdU-Alexa Fluor 488 imaging kit according to the manufacturer’s instructions (Thermo Fisher). Metaphases were post-fixed and hybridised with TelC-cy3 PNA probe.

Terra-fish

TERRA-FISH experiment was carried out as previously described (Azzalin et al., 2007) with minor modifications. Briefly cells were permeabilised 5 min with cold CSK buffer (10 mM Pipes pH7;100 mM NaCl; 300 mM sucrose; 3 mM MgCl2; 0.5% Triton X-100 and 10 mM of inhibitor Ribonucleoside Vanadyl Complex). After a wash in PBS1X, cells were fixed for 10 min in 3%formaldeyde solution and washed three times with PBS, followed by Immunofluorescence with primary anti-TRF2 (dilution 1/10.000, 1254 ab gift from T. de Lange). Nuclei were then incubated with secondary donkey anti-rabbit Alexa 488 antibody (1/400, Life Technologies) for 40 min at 37°C, washed three times in PBS1X and post fixed for 10 min. After incubation with ethanol series (70%, 80%, 90%, 100%) slides were dried O/N in the dark. TelC-cy3 PNA probe was used for TERRA detection and after incubation for 2 hr at RT, slides were washed 3 × 5 min in 50% formamide, 2XSSC at 39°C, 3 × 5 min in 2XSSC at 39°C and a final wash in 2XSSC at RT. Slides were dehydrated in successive ethanol baths, air-dried and mounted in antifade reagent (ProLong Gold, Invitrogen) containing DAPI and images were captured with Zeiss microscope using Carl Zeiss software. Quantification was performed using CellProfiler 3.1.8 software.

Chromatin immunoprecipitation (ChIP)

Chromatin preparation and ChIP experiments were performed as previously described (Porreca et al., 2018) with the following modifications: sonication of chromatin was performed for 20 min (30 s on/30 s off) in a Diagenode water bath-sonicator at high speed. 20–50 μg of chromatin was diluted 10 times in ChIP dilution buffer (20 mM Tris-HCl pH 8, 150 mM KCl, 2 mM EDTA pH 8, 1% Triton X-100, 0.1% SDS), pre-cleared with Dynabeads (Invitrogen) and incubated overnight with 2–5 μg of antibody (listed in the key resources table).

RNA dot blot

RNA extraction was carried out using RNeasy Mini Kit (Qiagen), according to the manufacturer instructions. 2 µg of RNA were denatured in 0.2 M NaOH by heating at 65°C for 10 min, incubated 5 min on ice and spotted onto a positively charged Biodyne B nylon membrane (Amersham Hybond, GE Healthcare). Membranes were UV-crosslinked (Stratalinker, 2000 kJ) and baked for 45 min at 80°C, followed by hybridisation at 42°C with digoxigenin (DIG)-labeled telomeric C-rich oligonucleotide TAA(CCCTAA)4, prepared using 3’ end labelled kit (Roche). Signal was revealed using the anti-DIG-alkaline phosphatase antibodies (Roche) and CDP-Star (Roche) following the manufacturer’s instructions. Images were captured using the Amersham Imager 680 (GE Healthcare) and analysed using the Image Studio Lite software.

18 s rRNA probe with sequence: 5’-CCATCCAATCGGTAGTAGCG was used for normalisation.

Northern blot

10 µg of RNA was denatured for 10 min at 65°C in sample buffer (50% formamide, 2.2M formaldehyde, 1X MOPS) followed by ice incubation for 5 min. 10X Dye buffer (50% Glycerol, 0.3% Bromophenol Blue, 4 mg/ml Ethidium Bromide) was added to each sample and all of them were run on a formaldehyde agarose gel (0.8% agarose, 1X MOPS, 6.5% formaldehyde) at 5V per cm in 1X MOPS buffer (0.2M MOPS, 50 mM NaOAc, 10 mM EDTA, RNAse free water). The gel was rinsed twice in water, washed twice with denaturation solution (1.5M NaCL, 0.05M NaOH), followed by additional three washes with 20XSSC before transferring the RNA on a positively charged Biodyne B nylon membrane (Amersham Hybond, GE Healthcare) using a neutral transfer in 20XSSC. The membrane was fixed and detected as described for the RNA dot blot.

Acknowledgements

We thank Titia de Lange for providing TRF1 antibody, Paul Freemont for providing PML antibody, Jo Murray for SMC5 antibody, Joachim Lingner for HT1080 cells and Zhou Songyang for TRF1 inducible CRISPR/Cas9 cells. Special thanks to Paulina Marzec for teaching RMP the PICh techniques in Boulton Lab and Jerome Dejardin for the constructive feedback. We thank Arturo Londono, Julia P Cooper, Julian Sale, Titia de Lange, Valerie Borel, Simon Boulton for their helpful comments. TRF1 MEFs were generated in Simon Boulton’s group from Titia de Lange’s mouse line.

Vannier lab’s work is supported by the London Institute of Medical Sciences (LMS), which receives its core funding from UKRI (MRC) and by an ERC Starter Grant (637798; MetDNASecStr). Rosa Maria Porreca is funded by ERC Starter Grant (637798; MetDNASecStr).

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Jean-Baptiste Vannier, Email: j.vannier@lms.mrc.ac.uk.

Raymund Wellinger, Université de Sherbrooke, Canada.

Jessica K Tyler, Weill Cornell Medicine, United States.

Funding Information

This paper was supported by the following grants:

  • European Commission 637798 MetDNASecStr to Rosa Maria Porreca, Emilia Herrera-Moyano, Eleni Skourti, Pui Pik Law, Jean-Baptiste Vannier.

  • Medical Research Council Telomere Replication and Stability to Roser Gonzalez Franco, Alex Montoya, Peter Faull, Holger Kramer, Jean-Baptiste Vannier.

Additional information

Competing interests

No competing interests declared.

Author contributions

Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Help in designing the project, conducted experiments and wrote the manuscript.

Data curation, Methodology, Conducted experiments.

Formal analysis, Methodology, Conducted experiments.

Data curation, Methodology, Conducted experiments.

Data curation, Methodology, Conducted experiments.

Data curation, Formal analysis, Methodology, Performed mass spectrometry and its analysis.

Data curation, Formal analysis, Methodology, Performed mass spectrometry and helped with its analysis.

Data curation, Formal analysis, Methodology, Performed mass spectrometry and its analysis.

Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing, Obtained the grant, Designed the project, Conducted experiments, Analysed the results and wrote the manuscript.

Additional files

Transparent reporting form

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for all figures. Proteomic data have been made available at ProteomeXchange, under the accession code PXD017022.

The following dataset was generated:

Porreca RM, Herrera-Moyano E, Skourti E, Law PP, Franco RG, Montoya A, Faull P, Kramer H, Vannier JB. 2020. Data from: TRF1 averts chromatin remodelling, recombination and replication dependent-Break Induced Replication at mouse telomeres. ProteomeXchange. PXD017022

References

  1. Amon JD, Koshland D. RNase H enables efficient repair of R-loop induced DNA damage. eLife. 2016;5:e20533. doi: 10.7554/eLife.20533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aragón L. The Smc5/6 complex: new and old functions of the enigmatic Long-Distance relative. Annual Review of Genetics. 2018;52:89–107. doi: 10.1146/annurev-genet-120417-031353. [DOI] [PubMed] [Google Scholar]
  3. Arora R, Lee Y, Wischnewski H, Brun CM, Schwarz T, Azzalin CM. RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells. Nature Communications. 2014;5:5220. doi: 10.1038/ncomms6220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science. 2007;318:798–801. doi: 10.1126/science.1147182. [DOI] [PubMed] [Google Scholar]
  5. Barefield C, Karlseder J. The BLM helicase contributes to telomere maintenance through processing of late-replicating intermediate structures. Nucleic Acids Research. 2012;40:7358–7367. doi: 10.1093/nar/gks407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bhowmick R, Minocherhomji S, Hickson ID. RAD52 Facilitates Mitotic DNA Synthesis Following Replication Stress. Molecular Cell. 2016;64:1117–1126. doi: 10.1016/j.molcel.2016.10.037. [DOI] [PubMed] [Google Scholar]
  7. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nature Medicine. 1997;3:1271–1274. doi: 10.1038/nm1197-1271. [DOI] [PubMed] [Google Scholar]
  8. Cesare AJ, Kaul Z, Cohen SB, Napier CE, Pickett HA, Neumann AA, Reddel RR. Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nature Structural & Molecular Biology. 2009;16:1244–1251. doi: 10.1038/nsmb.1725. [DOI] [PubMed] [Google Scholar]
  9. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nature Reviews Genetics. 2010;11:319–330. doi: 10.1038/nrg2763. [DOI] [PubMed] [Google Scholar]
  10. Chen Y-H, Choi K, Szakal B, Arenz J, Duan X, Ye H, Branzei D, Zhao X. Interplay between the Smc5/6 complex and the Mph1 helicase in recombinational repair. PNAS. 2009;106:21252–21257. doi: 10.1073/pnas.0908258106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chu HP, Froberg JE, Kesner B, Oh HJ, Ji F, Sadreyev R, Pinter SF, Lee JT. PAR-TERRA directs homologous sex chromosome pairing. Nature Structural & Molecular Biology. 2017;24:620–631. doi: 10.1038/nsmb.3432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Conomos D, Stutz MD, Hills M, Neumann AA, Bryan TM, Reddel RR, Pickett HA. Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells. The Journal of Cell Biology. 2012;199:893–906. doi: 10.1083/jcb.201207189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Conomos D, Pickett HA, Reddel RR. Alternative lengthening of telomeres: remodeling the telomere architecture. Frontiers in Oncology. 2013;3:27. doi: 10.3389/fonc.2013.00027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Conomos D, Reddel RR, Pickett HA. NuRD-ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination. Nature Structural & Molecular Biology. 2014;21:760–770. doi: 10.1038/nsmb.2877. [DOI] [PubMed] [Google Scholar]
  15. Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Molecular & Cellular Proteomics. 2014;13:2513–2526. doi: 10.1074/mcp.M113.031591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cox KE, Maréchal A, Flynn RL. SMARCAL1 resolves replication stress at ALT telomeres. Cell Reports. 2016;14:1032–1040. doi: 10.1016/j.celrep.2016.01.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cristofari G, Lingner J. Telomere length homeostasis requires that telomerase levels are limiting. The EMBO Journal. 2006;25:565–574. doi: 10.1038/sj.emboj.7600952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. d'Alcontres MS, Palacios JA, Mejias D, Blasco MA. TopoIIα prevents telomere fragility and formation of ultra thin DNA bridges during mitosis through TRF1-dependent binding to telomeres. Cell Cycle. 2014;13:1463–1481. doi: 10.4161/cc.28419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes & Development. 2005;19:2100–2110. doi: 10.1101/gad.1346005. [DOI] [PubMed] [Google Scholar]
  20. de Silanes IL, Graña O, De Bonis ML, Dominguez O, Pisano DG, Blasco MA. Identification of TERRA locus unveils a telomere protection role through association to nearly all chromosomes. Nature Communications. 2014;5:4723. doi: 10.1038/ncomms5723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Déjardin J, Kingston RE. Purification of proteins associated with specific genomic loci. Cell. 2009;136:175–186. doi: 10.1016/j.cell.2008.11.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Deng Z, Norseen J, Wiedmer A, Riethman H, Lieberman PM. TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. Molecular Cell. 2009;35:403–413. doi: 10.1016/j.molcel.2009.06.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Dilley RL, Verma P, Cho NW, Winters HD, Wondisford AR, Greenberg RA. Break-induced telomere synthesis underlies alternative telomere maintenance. Nature. 2016;539:54–58. doi: 10.1038/nature20099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Draskovic I, Arnoult N, Steiner V, Bacchetti S, Lomonte P, Londoño-Vallejo A. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination. PNAS. 2009;106:15726–15731. doi: 10.1073/pnas.0907689106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Feretzaki M, Renck Nunes P, Lingner J. Expression and differential regulation of human TERRA at several chromosome ends. RNA. 2019;25:1470–1480. doi: 10.1261/rna.072322.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. García-Cao M, O'Sullivan R, Peters AH, Jenuwein T, Blasco MA. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nature Genetics. 2004;36:94–99. doi: 10.1038/ng1278. [DOI] [PubMed] [Google Scholar]
  27. Garcia-Exposito L, Bournique E, Bergoglio V, Bose A, Barroso-Gonzalez J, Zhang S, Roncaioli JL, Lee M, Wallace CT, Watkins SC, Opresko PL, Hoffmann JS, O'Sullivan RJ. Proteomic profiling reveals a specific role for translesion DNA polymerase η in the alternative lengthening of telomeres. Cell Reports. 2016;17:1858–1871. doi: 10.1016/j.celrep.2016.10.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Glover TW, Stein CK. Induction of sister chromatid exchanges at common fragile sites. American Journal of Human Genetics. 1987;41:882–890. [PMC free article] [PubMed] [Google Scholar]
  29. Gu P, Min JN, Wang Y, Huang C, Peng T, Chai W, Chang S. CTC1 deletion results in defective telomere replication, leading to catastrophic telomere loss and stem cell exhaustion. The EMBO Journal. 2012;31:2309–2321. doi: 10.1038/emboj.2012.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ira G, Haber JE. Characterization of RAD51-independent break-induced replication that acts preferentially with short homologous sequences. Molecular and Cellular Biology. 2002;22:6384–6392. doi: 10.1128/MCB.22.18.6384-6392.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Karlseder J, Kachatrian L, Takai H, Mercer K, Hingorani S, Jacks T, de Lange T. Targeted deletion reveals an essential function for the telomere length regulator Trf1. Molecular and Cellular Biology. 2003;23:6533–6541. doi: 10.1128/MCB.23.18.6533-6541.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Khurana S, Kruhlak MJ, Kim J, Tran AD, Liu J, Nyswaner K, Shi L, Jailwala P, Sung MH, Hakim O, Oberdoerffer P. A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance. Cell Reports. 2014;8:1049–1062. doi: 10.1016/j.celrep.2014.07.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and Cancer. Science. 1994;266:2011–2015. doi: 10.1126/science.7605428. [DOI] [PubMed] [Google Scholar]
  34. Kim H, Li F, He Q, Deng T, Xu J, Jin F, Coarfa C, Putluri N, Liu D, Songyang Z. Systematic analysis of human telomeric dysfunction using inducible telosome/shelterin CRISPR/Cas9 knockout cells. Cell Discovery. 2017;3:17034. doi: 10.1038/celldisc.2017.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Lafuente-Barquero J, Luke-Glaser S, Graf M, Silva S, Gómez-González B, Lockhart A, Lisby M, Aguilera A, Luke B. The Smc5/6 complex regulates the yeast Mph1 helicase at RNA-DNA hybrid-mediated DNA damage. PLOS Genetics. 2017;13:e1007136. doi: 10.1371/journal.pgen.1007136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Lee YW, Arora R, Wischnewski H, Azzalin CM. TRF1 participates in chromosome end protection by averting TRF2-dependent telomeric R loops. Nature Structural & Molecular Biology. 2018;25:147–153. doi: 10.1038/s41594-017-0021-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Mao C, Davies D, Kerr IM, Stark GR. Mutant human cells defective in induction of major histocompatibility complex class II genes by interferon gamma. PNAS. 1993;90:2880–2884. doi: 10.1073/pnas.90.7.2880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Margalef P, Kotsantis P, Borel V, Bellelli R, Panier S, Boulton SJ. Stabilization of reversed replication forks by telomerase drives telomere catastrophe. Cell. 2018;172:439–453. doi: 10.1016/j.cell.2017.11.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Martínez P, Thanasoula M, Muñoz P, Liao C, Tejera A, McNees C, Flores JM, Fernández-Capetillo O, Tarsounas M, Blasco MA. Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased Cancer in mice. Genes & Development. 2009;23:2060–2075. doi: 10.1101/gad.543509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Marzec P, Armenise C, Pérot G, Roumelioti FM, Basyuk E, Gagos S, Chibon F, Déjardin J. Nuclear-receptor-mediated telomere insertion leads to genome instability in ALT cancers. Cell. 2015;160:913–927. doi: 10.1016/j.cell.2015.01.044. [DOI] [PubMed] [Google Scholar]
  41. McNees CJ, Tejera AM, Martínez P, Murga M, Mulero F, Fernandez-Capetillo O, Blasco MA. ATR suppresses telomere fragility and recombination but is dispensable for elongation of short telomeres by telomerase. The Journal of Cell Biology. 2010;188:639–652. doi: 10.1083/jcb.200908136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Miller KM, Rog O, Cooper JP. Semi-conservative DNA replication through telomeres requires Taz1. Nature. 2006;440:824–828. doi: 10.1038/nature04638. [DOI] [PubMed] [Google Scholar]
  43. Min J, Wright WE, Shay JW. Alternative lengthening of telomeres mediated by mitotic DNA synthesis engages Break-Induced replication processes. Molecular and Cellular Biology. 2017;37:e00226. doi: 10.1128/MCB.00226-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Minocherhomji S, Ying S, Bjerregaard VA, Bursomanno S, Aleliunaite A, Wu W, Mankouri HW, Shen H, Liu Y, Hickson ID. Replication stress activates DNA repair synthesis in mitosis. Nature. 2015;528:286–290. doi: 10.1038/nature16139. [DOI] [PubMed] [Google Scholar]
  45. Minocherhomji S, Hickson ID. Structure-specific endonucleases: guardians of fragile site stability. Trends in Cell Biology. 2014;24:321–327. doi: 10.1016/j.tcb.2013.11.007. [DOI] [PubMed] [Google Scholar]
  46. Montero JJ, López de Silanes I, Graña O, Blasco MA. Telomeric RNAs are essential to maintain telomeres. Nature Communications. 2016;7:12534. doi: 10.1038/ncomms12534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu JR. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. PNAS. 1988;85:6622–6626. doi: 10.1073/pnas.85.18.6622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Nakamura H, Morita T, Sato C. Structural organizations of replicon domains during DNA synthetic phase in the mammalian nucleus. Experimental Cell Research. 1986;165:291–297. doi: 10.1016/0014-4827(86)90583-5. [DOI] [PubMed] [Google Scholar]
  49. Neil AJ, Liang MU, Khristich AN, Shah KA, Mirkin SM. RNA-DNA hybrids promote the expansion of friedreich's ataxia (GAA)n repeats via break-induced replication. Nucleic Acids Research. 2018;46:3487–3497. doi: 10.1093/nar/gky099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. O'Sullivan RJ, Kubicek S, Schreiber SL, Karlseder J. Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. Nature Structural & Molecular Biology. 2010;17:1218–1225. doi: 10.1038/nsmb.1897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Ourliac-Garnier I, Londoño-Vallejo A. Telomere length analysis by quantitative fluorescent in situ hybridization (Q-FISH) Methods in Molecular Biology. 2011;735:21–31. doi: 10.1007/978-1-61779-092-8_3. [DOI] [PubMed] [Google Scholar]
  52. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annual Review of Genetics. 2008;42:301–334. doi: 10.1146/annurev.genet.41.110306.130350. [DOI] [PubMed] [Google Scholar]
  53. Pan X, Drosopoulos WC, Sethi L, Madireddy A, Schildkraut CL, Zhang D. FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres. PNAS. 2017;114:E5940–E5949. doi: 10.1073/pnas.1708065114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Pickett HA, Cesare AJ, Johnston RL, Neumann AA, Reddel RR. Control of telomere length by a trimming mechanism that involves generation of t-circles. The EMBO Journal. 2009;28:799–809. doi: 10.1038/emboj.2009.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Porreca RM, Glousker G, Awad A, Matilla Fernandez MI, Gibaud A, Naucke C, Cohen SB, Bryan TM, Tzfati Y, Draskovic I, Londoño-Vallejo A. Human RTEL1 stabilizes long G-overhangs allowing telomerase-dependent over-extension. Nucleic Acids Research. 2018;46:4533–4545. doi: 10.1093/nar/gky173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Potts PR, Porteus MH, Yu H. Human SMC5/6 complex promotes sister chromatid homologous recombination by recruiting the SMC1/3 cohesin complex to double-strand breaks. The EMBO Journal. 2006;25:3377–3388. doi: 10.1038/sj.emboj.7601218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Potts PR, Yu H. The SMC5/6 complex maintains telomere length in ALT Cancer cells through SUMOylation of telomere-binding proteins. Nature Structural & Molecular Biology. 2007;14:581–590. doi: 10.1038/nsmb1259. [DOI] [PubMed] [Google Scholar]
  58. Rosenfeld JA, Wang Z, Schones DE, Zhao K, DeSalle R, Zhang MQ. Determination of enriched histone modifications in non-genic portions of the human genome. BMC Genomics. 2009;10:143. doi: 10.1186/1471-2164-10-143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Roumelioti FM, Sotiriou SK, Katsini V, Chiourea M, Halazonetis TD, Gagos S. Alternative lengthening of human telomeres is a conservative DNA replication process with features of break-induced replication. EMBO Reports. 2016;17:1731–1737. doi: 10.15252/embr.201643169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Schoeftner S, Blasco MA. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. Nature Cell Biology. 2008;10:228–236. doi: 10.1038/ncb1685. [DOI] [PubMed] [Google Scholar]
  61. Sfeir A, Kosiyatrakul ST, Hockemeyer D, MacRae SL, Karlseder J, Schildkraut CL, de Lange T. Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell. 2009;138:90–103. doi: 10.1016/j.cell.2009.06.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nature Protocols. 2006;1:2856–2860. doi: 10.1038/nprot.2006.468. [DOI] [PubMed] [Google Scholar]
  63. Sotiriou SK, Kamileri I, Lugli N, Evangelou K, Da-Ré C, Huber F, Padayachy L, Tardy S, Nicati NL, Barriot S, Ochs F, Lukas C, Lukas J, Gorgoulis VG, Scapozza L, Halazonetis TD. Mammalian RAD52 functions in Break-Induced replication repair of collapsed DNA replication forks. Molecular Cell. 2016;64:1127–1134. doi: 10.1016/j.molcel.2016.10.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Tong AS, Stern JL, Sfeir A, Kartawinata M, de Lange T, Zhu XD, Bryan TM. ATM and ATR signaling regulate the recruitment of human telomerase to telomeres. Cell Reports. 2015;13:1633–1646. doi: 10.1016/j.celrep.2015.10.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Tumini E, Barroso S, -Calero CP, Aguilera A. Roles of human POLD1 and POLD3 in genome stability. Scientific Reports. 2016;6:38873. doi: 10.1038/srep38873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Tutton S, Azzam GA, Stong N, Vladimirova O, Wiedmer A, Monteith JA, Beishline K, Wang Z, Deng Z, Riethman H, McMahon SB, Murphy M, Lieberman PM. Subtelomeric p53 binding prevents accumulation of DNA damage at human telomeres. The EMBO Journal. 2016;35:193–207. doi: 10.15252/embj.201490880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Vannier JB, Pavicic-Kaltenbrunner V, Petalcorin MI, Ding H, Boulton SJ. RTEL1 dismantles T loops and counteracts telomeric G4-DNA to maintain telomere integrity. Cell. 2012;149:795–806. doi: 10.1016/j.cell.2012.03.030. [DOI] [PubMed] [Google Scholar]
  68. Wu G, Lee WH, Chen PL. NBS1 and TRF1 colocalize at promyelocytic leukemia bodies during late S/G2 phases in immortalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. The Journal of Biological Chemistry. 2000;275:30618–30622. doi: 10.1074/jbc.C000390200. [DOI] [PubMed] [Google Scholar]
  69. Wu P, Takai H, de Lange T. Telomeric 3' overhangs derive from resection by Exo1 and apollo and fill-in by POT1b-associated CST. Cell. 2012;150:39–52. doi: 10.1016/j.cell.2012.05.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Research. 1999;59:4175–4179. [PubMed] [Google Scholar]
  71. Yu TY, Kao YW, Lin JJ. Telomeric transcripts stimulate telomere recombination to suppress senescence in cells lacking telomerase. PNAS. 2014;111:3377–3382. doi: 10.1073/pnas.1307415111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Zaaijer S, Shaikh N, Nageshan RK, Cooper JP. Rif1 regulates the fate of DNA entanglements during mitosis. Cell Reports. 2016;16:148–160. doi: 10.1016/j.celrep.2016.05.077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Zimmermann M, Kibe T, Kabir S, de Lange T. TRF1 negotiates TTAGGG repeat-associated replication problems by recruiting the BLM helicase and the TPP1/POT1 repressor of ATR signaling. Genes & Development. 2014;28:2477–2491. doi: 10.1101/gad.251611.114. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision letter

Editor: Raymund Wellinger1
Reviewed by: Raymund Wellinger2

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Acceptance summary:

Telomeric repeat sequences are prone to induce replication stress and one of the core telomere binding proteins, TRF1, is thought to counteract these problems. The molecular mechanisms coming into play upon TRF1 loss were not clearly defined though. This study combines an inducible TRF1 loss with telomere-targeted proteomics to analyze the incurring changes. The results show that loss of TRF1 causes important alterations in telomere associated proteins and the new profile resembles in a number of ways that of cells in which telomeres are maintained by telomerase-independent mechanisms, named ALT. The presence of DNA repair proteins (MRN complex, the SMC5/6 complex), some increases in telomere colocalization with PML bodies, sister chromatid exchanges and clear signs of increased TERRA transcription and mitotic break-induced replication are part of these phenotypes. The data also show that these early ALT phenotypes can be differentiated from drug induced replication stress, and part of this ALT response is conserved in human cells. These studies therefore point to a critical role for TRF1 in preventing the emergence of ALT and hence immortalization of cells. Given that the details for how ALT actually is initiated remained unclear, these findings are an important step forward and will spur new research into that question.

Decision letter after peer review:

Thank you for submitting your article "TRF1 prevents permissive DNA damage response, recombination and Break Induced Replication at telomeres" for consideration by eLife. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jessica Tyler as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Thanks for your submission and support of eLife. As mentioned above, your study has been evaluated by three referees and after discussion, they unanimously thought that your manuscript is a nicely crafted proteomics study that does directly support a much speculated, but not evidence based, theory on replication stress causing initial events of the ALT mechanism. The inducible loss of TRF1 is a very efficient way to study these events and the results are viewed as robust and clear. This is an important finding that has the potential to lead to new investigations on how ALT arises and bring our understanding of that to a new level. However, the reviewers also thought that the general relevance of the study would increase substantially, if experiments directed at dissecting the role of TRF1 could be added. Such results would really elevate the study to a prime candidate for eLife, where we strive to publish only the most significant and outstanding advances in the field.

Therefore, the reviewers agreed that the following two approaches would be required for the paper to go forward:

1) Are the detected molecular events after TRF1 loss a consequence of chronic replication stress or does TRF1 directly somehow inhibit these events? In order to test these alternatives, one could induce strong replication stress in the presence of TRF1. The experiment would be to treat cells with Aphidicolin (or HU) and assess initial ALT phenotypes directly. SMC5/6 Chip, impact on TERRA, chromatin changes, and ideally some phenotypic outcome at telomeres (SCE exchanges, or mitotic synthesis).

2) Are these events also occurring in human cells suffering replication stress and or loss of TRF1? Reviewers suggest to use a long telomere HeLa variant (1.2.11; or 1.3) and repress TRF1 and/or apply replication stress compounds as above. Readouts again would be characteristic molecular events for ALT.

eLife. 2020 Jan 14;9:e49817. doi: 10.7554/eLife.49817.sa2

Author response


Thanks for your submission and support of eLife. As mentiioned above, your study has been evaluated by three referees and after discussion, they unanimously thought that your manuscript is a nicely crafted proteomics study that does directly support a much speculated, but not evidence based, theory on replication stress causing initial events of the ALT mechanism. The inducible loss of TRF1 is a very efficient way to study these events and the results are viewed as robust and clear. This is an important finding that has the potential to lead to new investigations on how ALT arises and bring our understanding of that to a new level. However, the reviewers also thought that the general relevance of the study would increase substantially, if experiments directed at dissecting the role of TRF1 could be added. Such results would really elevate the study to a prime candidate for eLife, where we strive to publish only the most significant and outstanding advances in the field.

Therefore, the reviewers agreed that the following two approaches would be required for the paper to go forward:

1) Are the detected molecular events after TRF1 loss a consequence of chronic replication stress or does TRF1 directly somehow inhibit these events? In order to test these alternatives, one could induce strong replication stress in the presence of TRF1. The experiment would be to treat cells with Aphidicolin (or HU) and assess initial ALT phenotypes directly. SMC5/6 Chip, impact on TERRA, chromatin changes, and ideally some phenotypic outcome at telomeres (SCE exchanges, or mitotic synthesis).

We thank the reviewers for their constructive suggestions. We treated wild-type MEFs with aphidicolin (APH) in order to induce replication stress, as it is well described to induce telomere fragility or multi-telomeric signal (Sfeir et al., 2009; Martinez et al., 2009). We have now included new paragraphs in the manuscript describing these new experiments.

We treated wt MEFs for 3 days (0.4µM APH) as it was the longest treatment that cells could support. Under these conditions, we could not detect the recruitment of any of the chromatin remodellers and DNA repair factors BRCA1, MTA1, CHD4, ZNF827 and BAZ1b that we characterised at TRF1 depleted telomeres by ChIP-dot blot (Figure 2—figure supplement 1). We could not test for the recruitment of mouse SMC5/6 to telomeres due to the lack of efficient ChIP grade antibodies. However, we looked for all ALT-associated telomere phenotypes present in TRF1-/-MEFs: APBs formation (Figure 2—figure supplement 1C), TERRAs (Figure 3—figure supplement 1F) and T-SCEs (Figure 2—figure supplement 2B).

1) We observe a general increase of PML foci in wt MEFs treated with APH, however the total number of APBs is not increased in treated cells compared to untreated. On the contrary, the number of PML-telomere co-localisations vs total number of PML significantly decreases in treated cells (Figure 2—figure supplement 1C).

2) wt MEFs treated with APH present an increase of TERRA molecules (Figure 3—figure supplement 1, E-F). This is similar to the increase in HMW TERRAs observed in TRF1-/- MEFs and could be a consequence of the replication stress.

3) Finally, we also quantified T-SCEs in mouse cells treated with APH and identified an increase in single exchanges, which are characteristic of conservative DNA synthesis – Break Induced Replication. However, the absence of reciprocal exchanges between telomere chromatids indicates that APH-dependent replication stress does not trigger an HR activation/response (up to 3 days) and this is specific to the function of TRF1 (Figure 2—figure supplement 2B).

This comparison analysis is essential for the understanding of the direct and indirect molecular events of repair and recombination that are arising at TRF1 depleted telomeres. We propose that in the absence of TRF1, telomeric chromatin re-arrange to a more HR prone environment and this is mediated by Chromatin remodellers including NuRD. Telomeres associated to PML to form APBs, which is essential for HR. At the same time, TRF1-dependent replication stress activates POLD3-dependent BIR to restart stalled/collapsed telomeric replication forks.

2) Are these events also occurring in human cells suffering replication stress and or loss of TRF1? Reviewers suggest to use a long telomere HeLa variant (1.2.11; or 1.3) and repress TRF1 and/or apply replication stress compounds as above. Readouts again would be characteristic molecular events for ALT.

Considering the important information gained by looking at the differences and similarities between APH- and TRF1-dependent replication stress in mouse cells, we then decided to focus our efforts on validating the function of TRF1 in suppressing characteristic molecular ALT events in human cells. We use small RNA interference against TRF1 in HT1080-ST cells (long telomeres) and looked at characteristic molecular events of ALT, as APBs, TERRAs, BIR and HR. We have now included a new paragraph and supplemental figures describing this part (Figure 2—figure supplement 4 and Figure 3—figure supplement 2).

Briefly, we show that:

1) TRF1-depleted HT1080-ST cells (Figure 2—figure supplement 4A) present increased APBs (Figure 2—figure supplement 4B) similar to the mouse cells.

2) We looked for the accumulation of TERRA molecules in HT1080ST (siRNA-day 6) and HeLa (Crispr/Cas9-day 15) cells depleted for TRF1. After 6 days, we could not detect a significant increase in TERRAs (Figure 3—figure supplement 2A) and neither after 15 days culturing HeLa stable TRF1 KO (Figure 3—figure supplement 2B).

3) We measured sister chromatid exchanges at telomeres in HT1080-ST depleted for TRF1 with siRNA. We observed an increase in single exchanges (Figure 2—figure supplement 4C) that we reported to be a mark of BIR in TRF1-deficient murine cells. However, we could not detect any differences for double exchanges between ctl and TRF1 siRNA treated cells (Figure 2—figure supplement 4C).

In conclusion, some of the TRF1 functions are conserved between mouse and human. For both species, TRF1 suppresses telomere fragility and therefore is essential to facilitate DNA replication through telomeric repeats. We now show that like for mouse TRF1, its human homolog is essential to suppress APBs formation and BIR, which is likely to be the activated mechanism to rescue stalled/collapsed telomeric forks.

We have now included a new paragraph in the Discussion section describing the differences between mouse and human TERRAs.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Citations

    1. Porreca RM, Herrera-Moyano E, Skourti E, Law PP, Franco RG, Montoya A, Faull P, Kramer H, Vannier JB. 2020. Data from: TRF1 averts chromatin remodelling, recombination and replication dependent-Break Induced Replication at mouse telomeres. ProteomeXchange. PXD017022 [DOI] [PMC free article] [PubMed]

    Supplementary Materials

    Figure 1—source data 1. TRF1F/F MEFs western blot.

    Related to Figure 1B.

    Figure 1—source data 2. PICh data (TRF1F/F telo vs TRF1-/- telo).

    Related to Figure 1D.

    elife-49817-fig1-data2.xlsx (227.8KB, xlsx)
    Figure 1—source data 3. PICh data.

    Related to Figure 1F.

    elife-49817-fig1-data3.xlsx (219.7KB, xlsx)
    Figure 2—source data 1. Control specificity of proteomic binding (TRF1-/- telo vs TRF1-/- scbl).

    Related to Figure 2A.

    Figure 2—source data 2. ChIP quantification in TRF1F/F MEFs.

    Related to Figure 2B.

    Figure 2—source data 3. Quantification of APBs in TRF1F/F MEFs.

    Related to Figure 2C.

    Figure 2—source data 4. T-SCEs quantification in TRF1F/F MEFs.

    Related to Figure 2D.

    Figure 2—figure supplement 1—source data 1. Alu probe control for ChIP quantification in TRF1F/F MEFs.

    Related to Figure 2—figure supplement 1A.

    Figure 2—figure supplement 1—source data 2. ChIP quantification in MEFs treated with APH.

    Related to Figure 2—figure supplement 1B.

    Figure 2—figure supplement 1—source data 3. Quantification of APBs in MEFs treated with APH.

    Related to Figure 2—figure supplement 1C.

    Figure 2—figure supplement 2—source data 1. T-SCEs quantification in TRF1F/F MEFs.

    Related to Figure 2—figure supplement 2A.

    Figure 2—figure supplement 2—source data 2. T-SCEs quantification of MEFs treated with APH.

    Related to Figure 2—figure supplement 2B.

    Figure 3—source data 1. Quantification of Telomeric RNA molecules by dot-blot in TRF1F/F MEFs.

    Related to Figure 3A.

    Figure 3—source data 2. Quantification of TERRAs by Northern.

    Related to Figure 3B.

    elife-49817-fig3-data2.xlsx (761.2KB, xlsx)
    Figure 3—source data 3. Quantification of number of TERRA foci.

    Related to Figure 3C.

    Figure 3—figure supplement 1—source data 1. WB of TRF1F/F primary MEFs and immortalized after 4 days of CRE.

    Related to Figure 3—figure supplement 1A.

    Figure 3—figure supplement 1—source data 2. Telomeric RNA molecules by dot-blot in primary TRF1F/F MEFs and immortalized after 4 days of CRE.

    Related to Figure 3—figure supplement 1B.

    Figure 3—figure supplement 1—source data 3. Quantification of Telomeric RNA molecules by dot-blot in primary TRF1F/F MEFs and immortalized after 4 days of CRE.

    Related to Figure 3—figure supplement 1C.

    Figure 3—figure supplement 1—source data 4. TERRAs by Northern in TRF1F/F MEFs.

    Related to Figure 3—figure supplement 1D.

    Figure 3—figure supplement 1—source data 5. Quantification of Telomeric RNA molecules by dot-blot in wt MEFs treated with APH.

    Related to Figure 3—figure supplement 1E.

    Figure 3—figure supplement 1—source data 6. TERRAs by Northern in wt MEFs treated with APH.

    Related to Figure 3—figure supplement 1F.

    Figure 3—figure supplement 2—source data 1. Telomere length by Southern in TRF1F/F MEFs.

    Related to Figure 3—figure supplement 2A.

    Figure 3—figure supplement 2—source data 2. Telomerase activity by TRAP in TRF1F/F MEFs.

    Related to Figure 3—figure supplement 2B.

    Figure 3—figure supplement 2—source data 3. c-circle amplification assay in TRF1F/F MEFs and U2OS (+ctl).

    Related to Figure 3—figure supplement 2C.

    Figure 4—source data 1. KD of TRF1 in HT1080-ST cells.

    Related to Figure 4A.

    Figure 4—source data 2. Quantification of APBs in HT1080-ST TRF1 KD.

    Related to Figure 4B.

    Figure 4—source data 3. T-SCEs quantification in HT1080-ST TRF1 KD.

    Related to Figure 4C.

    Figure 4—figure supplement 1—source data 1. Quantification of Telomeric RNA molecules by dot-blot in HT1080-ST TRF1 KD.

    Related to Figure 4—figure supplement 1A.

    Figure 4—figure supplement 1—source data 2. KO efficiency and quantification of Telomeric RNA molecules by dot-blot in Dox inducible HeLa CRISPR/Cas9 system.

    Related to Figure 4—figure supplement 1B.

    Figure 5—source data 1. Quantification of BrdU-TRF2 co-localisation in S and non-S nuclei.

    Related to Figure 5C.

    Figure 5—source data 2. Quantification of Mitosis DNA synthesis in TRF1F/F MEFs and at telomeres.

    Related to Figure 5D and F.

    Figure 6—source data 1. WB and Quantification of SMC5 knock-down efficiency in TRF1F/F MEFs.

    Related to Figure 6A and B.

    Figure 6—source data 2. POLD3 mRNA levels after KD in TRF1F/F MEFs.

    Related to Figure 6C.

    Figure 6—source data 3. Quantification of Mitosis DNA synthesis at telomeres in TRF1F/F MEFs with and without POLD3 and SMC5.

    Related to Figure 6D and E.

    Figure 6—figure supplement 1—source data 1. Population doublings in TRF1F/F MEFs with and without POLD3 and SMC5.

    Related to Figure 6—figure supplement 1A.

    Figure 6—figure supplement 1—source data 2. Number of S- and non-S phase in TRF1F/F MEFs with and without POLD3 and SMC5.

    Related to Figure 6—figure supplement 1VB.

    Figure 6—figure supplement 2—source data 1. Fragile telomeres in TRF1F/F MEFs with and without POLD3 and SMC5.

    Related to Figure 6—figure supplement 2C.

    Figure 7—source data 1. APBs co-localisations quantification in TRF1F/F MEFs with and without POLD3 and SMC5.

    Related to Figure 7A.

    Figure 7—source data 2. T-SCEs quantification in TRF1F/F MEFs with and without POLD3 and SMC5.

    Related to Figure 7B.

    Figure 7—source data 3. Quantification of Telomeric RNA molecules by dot-blot in TRF1F/F MEFs with and without POLD3 and SMC5.

    Related to Figure 7C.

    Figure 7—figure supplement 1—source data 1. T-SCEs quantification in TRF1F/F MEFs with and without POLD3 and SMC5.

    Related to Figure 7—figure supplement 1A. Accession code for the proteomic data will be made available before publication on public repository PRIDE.

    Transparent reporting form

    Data Availability Statement

    All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for all figures. Proteomic data have been made available at ProteomeXchange, under the accession code PXD017022.

    The following dataset was generated:

    Porreca RM, Herrera-Moyano E, Skourti E, Law PP, Franco RG, Montoya A, Faull P, Kramer H, Vannier JB. 2020. Data from: TRF1 averts chromatin remodelling, recombination and replication dependent-Break Induced Replication at mouse telomeres. ProteomeXchange. PXD017022


    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES